Liver diseases: epidemiology, causes, trends and predictions
Santos, A. A. et al. Spatial metabolomics and its application in the liver. Hepatology 79, 1158–1179 (2024).
Google Scholar
Schulze, R. J. et al. The cell biology of the hepatocyte: a membrane trafficking machine. J. Cell Biol. 218, 2096–2112 (2019).
Google Scholar
Han, H. et al. Danger signals in liver injury and restoration of homeostasis. J. Hepatol. 73, 933–951 (2020).
Google Scholar
Devarbhavi, H. et al. Global burden of liver disease: 2023 update. J. Hepatol. 79, 516–537 (2023).
Google Scholar
Wong, M. C. S. et al. The changing epidemiology of liver diseases in the Asia-Pacific region. Nat. Rev. Gastroenterol. Hepatol. 16, 57–73 (2019).
Google Scholar
Vilar-Gomez, E. & Chalasani, N. Non-invasive assessment of non-alcoholic fatty liver disease: Clinical prediction rules and blood-based biomarkers. J. Hepatol. 68, 305–315 (2018).
Google Scholar
Tapper, E. B. & Parikh, N. D. Diagnosis and management of cirrhosis and its complications: a review. JAMA 329, 1589–1602 (2023).
Google Scholar
Ginès, P. et al. Liver cirrhosis. Lancet 398, 1359–1376 (2021).
Google Scholar
GBD 2017 Cirrhosis Collaborators. The global, regional, and national burden of cirrhosis by cause in 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet Gastroenterol Hepatol. 5, 245–266 (2020).
Sung, H. et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 71, 209–249 (2021).
Google Scholar
Stanaway, J. D. et al. The global burden of viral hepatitis from 1990 to 2013: findings from the Global Burden of Disease Study 2013. Lancet 388, 1081–1088 (2016).
Google Scholar
Rehm, J. et al. Alcohol as a risk factor for liver cirrhosis: a systematic review and meta-analysis. Drug Alcohol Rev. 29, 437–445 (2010).
Google Scholar
Le, M. H. et al. 2019 Global NAFLD Prevalence: a systematic review and meta-analysis. Clin. Gastroenterol. Hepatol. 20, 2809–2817.e2828 (2022).
Google Scholar
Han, J. et al. Declining disease burden of HCC in the United States, 1992-2017: a population-based analysis. Hepatology 76, 576–588 (2022).
Google Scholar
Chen, J. et al. Sedentary lifestyle, physical activity, and gastrointestinal diseases: evidence from Mendelian randomization analysis. EBioMedicine 103, 105110 (2024).
Google Scholar
Ivancovsky Wajcman, D. et al. A narrative review of lifestyle management guidelines for metabolic dysfunction-associated steatotic liver disease. Hepatology (2024).
Wong, V. W., Ekstedt, M., Wong, G. L. & Hagström, H. Changing epidemiology, global trends and implications for outcomes of NAFLD. J. Hepatol. 79, 842–852 (2023).
Google Scholar
Sheron, N. Alcohol and liver disease in Europe-Simple measures have the potential to prevent tens of thousands of premature deaths. J. Hepatol. 64, 957–967 (2016).
Google Scholar
Seitz, H. K. et al. Alcoholic liver disease. Nat. Rev. Dis. Prim. 4, 16 (2018).
Google Scholar
Askgaard, G. et al. Population-based study of alcohol-related liver disease in england in 2001-2018: influence of socioeconomic position. Am. J. Gastroenterol. 119, 1337–1345 (2024).
Google Scholar
Younossi, Z. M., Wong, G., Anstee, Q. M. & Henry, L. The global burden of liver disease. Clin. Gastroenterol. Hepatol. 21, 1978–1991 (2023).
Google Scholar
Jiang, H., Room, R. & Hao, W. Alcohol and related health issues in China: action needed. Lancet Glob. Health 3, e190–e191 (2015).
Google Scholar
Manns, M. P. & Maasoumy, B. Breakthroughs in hepatitis C research: from discovery to cure. Nat. Rev. Gastroenterol. Hepatol. 19, 533–550 (2022).
Google Scholar
Trickey, A. et al. The effectiveness of low dead space syringes for reducing the risk of hepatitis C virus acquisition among people who inject drugs: findings from a National Survey in England, Wales, and Northern Ireland. Clin. Infect. Dis. 75, 1073–1077 (2022).
Google Scholar
Falade-Nwulia, O. et al. Oral direct-acting agent therapy for hepatitis C virus infection: a systematic review. Ann. Intern Med 166, 637–648 (2017).
Google Scholar
Polaris Observatory HCV Collaborators. Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study. Lancet Gastroenterol Hepatol. 2, 161–176 (2017).
Lemon, S. M., Ott, J. J., Van Damme, P. & Shouval, D. Type A viral hepatitis: a summary and update on the molecular virology, epidemiology, pathogenesis and prevention. J. Hepatol. 68, 167–184 (2017).
Hakim, M. S. et al. The global burden of hepatitis E outbreaks: a systematic review. Liver Int. 37, 19–31 (2017).
Google Scholar
Bray, F. et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 74, 229–263 (2024).
Google Scholar
Barouki, R. et al. The exposome and liver disease—how environmental factors affect liver health. J. Hepatol. 79, 492–505 (2023).
Google Scholar
Rani, J., Dhull, S. B., Rose, P. K. & Kidwai, M. K. Drug-induced liver injury and anti-hepatotoxic effect of herbal compounds: a metabolic mechanism perspective. Phytomedicine 122, 155142 (2024).
Google Scholar
Organization, W. H. WHO Position Paper on Hepatitis A Vaccines (2022).
Jacobsen, K. H. Globalization and the changing epidemiology of hepatitis A virus. Cold Spring Harb. Perspect. Med. 8 (2018).
Jacobsen, K. H. & Wiersma, S. T. Hepatitis A virus seroprevalence by age and world region, 1990 and 2005. Vaccine 28, 6653–6657 (2010).
Google Scholar
Van Damme, P. et al. Hepatitis A virus infection. Nat. Rev. Dis. Prim. 9, 51 (2023).
Google Scholar
Migueres, M., Lhomme, S. & Izopet, J. Hepatitis A: epidemiology, high-risk groups, prevention and research on antiviral treatment. Viruses 13 (2021).
Khuroo, M. S., Khuroo, M. S. & Khuroo, N. S. Transmission of Hepatitis E virus in developing countries. Viruses 8 (2016).
Zeng, D. Y. et al. Global burden of acute viral hepatitis and its association with socioeconomic development status, 1990-2019. J. Hepatol. 75, 547–556 (2021).
Google Scholar
Ricci, A. et al. Public health risks associated with hepatitis E virus (HEV) as a food-borne pathogen. EFSA J. 15, e04886 (2017).
Google Scholar
Thom, K. et al. Hepatitis E virus (HEV) in Scotland: evidence of recent increase in viral circulation in humans. Euro Surveill. 23 (2018).
Dalton, H. R. & Izopet, J. Transmission and epidemiology of Hepatitis E virus genotype 3 and 4 infections. Cold Spring Harb. Perspect. Med. 8 (2018).
Mahrt, H. et al. Continuous decline of hepatitis E virus seroprevalence in southern Germany despite increasing notifications, 2003-2015. Emerg. Microbes Infect. 7, 133 (2018).
Google Scholar
Shen, T. et al. Incidence and etiology of drug-induced liver injury in Mainland China. Gastroenterology 156, 2230–2241.e2211 (2019).
Google Scholar
Hussaini, S. H., O’Brien, C. S., Despott, E. J. & Dalton, H. R. Antibiotic therapy: a major cause of drug-induced jaundice in southwest England. Eur. J. Gastroenterol. Hepatol. 19, 15–20 (2007).
Google Scholar
de Abajo, F. J., Montero, D., Madurga, M. & García Rodríguez, L. A. Acute and clinically relevant drug-induced liver injury: a population based case-control study. Br. J. Clin. Pharm. 58, 71–80 (2004).
Google Scholar
Sgro, C. et al. Incidence of drug-induced hepatic injuries: a French population-based study. Hepatology 36, 451–455 (2002).
Google Scholar
Björnsson, E. S. et al. Incidence, presentation, and outcomes in patients with drug-induced liver injury in the general population of Iceland. Gastroenterology 144, 1419–1425 (2013).
Google Scholar
Vega, M. et al. The incidence of drug- and herbal and dietary supplement-induced liver injury: preliminary findings from gastroenterologist-based surveillance in the population of the state of Delaware. Drug Saf. 40, 783–787 (2017).
Google Scholar
Suk, K. T. et al. A prospective nationwide study of drug-induced liver injury in Korea. Am. J. Gastroenterol. 107, 1380–1387 (2012).
Google Scholar
Organization, W. H. Estimated Mortality Rate from Cirrhosis and Other Chronic Liver Diseases (2019).
GBD 2019 Hepatitis B Collaborators. Global, regional, and national burden of hepatitis B, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet Gastroenterol Hepatol. 7, 796–829 (2022).
Indolfi, G. et al. Hepatitis B virus infection in children and adolescents. Lancet Gastroenterol. Hepatol. 4, 466–476 (2019).
Google Scholar
Polaris Observatory Collaborators. Global prevalence, cascade of care, and prophylaxis coverage of hepatitis B in 2022: a modelling study. Lancet Gastroenterol Hepatol. 8, 879–907 (2023).
Cooke, G. S. et al. Accelerating the elimination of viral hepatitis: a Lancet Gastroenterology & Hepatology Commission. Lancet Gastroenterol. Hepatol. 4, 135–184 (2019).
Google Scholar
Rochwerg, B. et al. High flow nasal cannula compared with conventional oxygen therapy for acute hypoxemic respiratory failure: a systematic review and meta-analysis. Intensive Care Med 45, 563–572 (2019).
Google Scholar
Sarin, S. K. et al. Liver diseases in the Asia-Pacific region: a Lancet Gastroenterology & Hepatology Commission. Lancet Gastroenterol. Hepatol. 5, 167–228 (2020).
Google Scholar
Pimpin, L. et al. Burden of liver disease in Europe: epidemiology and analysis of risk factors to identify prevention policies. J. Hepatol. 69, 718–735 (2018).
Google Scholar
Asrani, S. K., Devarbhavi, H., Eaton, J. & Kamath, P. S. Burden of liver diseases in the world. J. Hepatol. 70, 151–171 (2019).
Google Scholar
Rizzetto, M., Hamid, S. & Negro, F. The changing context of hepatitis D. J. Hepatol. 74, 1200–1211 (2021).
Google Scholar
Chen, H. Y. et al. Prevalence and burden of hepatitis D virus infection in the global population: a systematic review and meta-analysis. Gut 68, 512–521 (2019).
Google Scholar
Stockdale, A. J. et al. The global prevalence of hepatitis D virus infection: systematic review and meta-analysis. J. Hepatol. 73, 523–532 (2020).
Google Scholar
Polaris Observatory HCV Collaborators. Global change in hepatitis C virus prevalence and cascade of care between 2015 and 2020: a modelling study. Lancet Gastroenterol Hepatol. 7, 396-415 (2022).
Mohd Hanafiah, K., Groeger, J., Flaxman, A. D. & Wiersma, S. T. Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. Hepatology 57, 1333–1342 (2013).
Google Scholar
Younossi, Z. M. et al. The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review. Hepatology 77, 1335–1347 (2023).
Google Scholar
Younossi, Z. et al. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. Nat. Rev. Gastroenterol. Hepatol. 15, 11–20 (2018).
Google Scholar
Yip, T. C. et al. Geographical similarity and differences in the burden and genetic predisposition of NAFLD. Hepatology 77, 1404–1427 (2023).
Google Scholar
Riazi, K. et al. The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis. Lancet Gastroenterol. Hepatol. 7, 851–861 (2022).
Google Scholar
Armstrong, M. J. et al. Presence and severity of non-alcoholic fatty liver disease in a large prospective primary care cohort. J. Hepatol. 56, 234–240 (2012).
Google Scholar
Tarnoki, A. D. et al. Heritability of non-alcoholic fatty liver disease and association with abnormal vascular parameters: a twin study. Liver Int. 32, 1287–1293 (2012).
Google Scholar
Zhou, F. et al. Unexpected rapid increase in the burden of NAFLD in China from 2008 to 2018: a systematic review and meta-analysis. Hepatology 70, 1119–1133 (2019).
Google Scholar
Xiao, J. et al. Global liver disease burdens and research trends: analysis from a Chinese perspective. J. Hepatol. 71, 212–221 (2019).
Google Scholar
Man, S. et al. Prevalence of liver steatosis and fibrosis in the general population and various high-risk populations: a nationwide study with 5.7 million adults in China. Gastroenterology 165, 1025–1040 (2023).
Google Scholar
Ito, T. et al. The epidemiology of NAFLD and lean NAFLD in Japan: a meta-analysis with individual and forecasting analysis, 1995-2040. Hepatol. Int. 15, 366–379 (2021).
Google Scholar
Park, J. et al. NASH/liver fibrosis prevalence and incidence of nonliver comorbidities among people with NAFLD and incidence of NAFLD by metabolic comorbidities: lessons from South Korea. Dig. Dis. 39, 634–645 (2021).
Google Scholar
Younossi, Z. M. et al. Global epidemiology of nonalcoholic fatty liver disease-meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology 64, 73–84 (2016).
Google Scholar
Ahmed, M. H. et al. Non-alcoholic fatty liver disease in africa and middle east: an attempt to predict the present and future implications on the healthcare system. Gastroenterol. Res 10, 271–279 (2017).
Google Scholar
Long, M. T., Noureddin, M. & Lim, J. K. AGA clinical practice update: diagnosis and management of nonalcoholic fatty liver disease in lean individuals: expert review. Gastroenterology 163, 764–774.e761 (2022).
Google Scholar
Tang, A. et al. Comparative burden of metabolic dysfunction in lean NAFLD vs non-lean NAFLD—a systematic review and meta-analysis. Clin. Gastroenterol. Hepatol. 21, 1750–1760.e1712 (2023).
Google Scholar
Eslam, M. et al. Metabolic (dysfunction)-associated fatty liver disease in individuals of normal weight. Nat. Rev. Gastroenterol. Hepatol. 19, 638–651 (2022).
Google Scholar
Rehm, J., Samokhvalov, A. V. & Shield, K. D. Global burden of alcoholic liver diseases. J. Hepatol. 59, 160–168 (2013).
Google Scholar
WHO. Global Status Report on Alcohol and Health 2018 450 (WHO, 2018).
Xiao, J. et al. Epidemiological realities of alcoholic liver disease: global burden, research trends, and therapeutic promise. Gene Expr. 20, 105–118 (2020).
Google Scholar
Kim, J. U. et al. Effect of COVID-19 lockdown on alcohol consumption in patients with pre-existing alcohol use disorder. Lancet Gastroenterol. Hepatol. 5, 886–887 (2020).
Google Scholar
Kilian, C. et al. Changes in alcohol use during the COVID-19 pandemic in Europe: a meta-analysis of observational studies. Drug Alcohol Rev. 41, 918–931 (2022).
Google Scholar
Zhong, P. et al. COVID-19-associated gastrointestinal and liver injury: clinical features and potential mechanisms. Signal Transduct. Target Ther. 5, 256 (2020).
Google Scholar
Lazarus, J. V. et al. Advancing the global public health agenda for NAFLD: a consensus statement. Nat. Rev. Gastroenterol. Hepatol. 19, 60–78 (2022).
Google Scholar
Meyers, J. L. et al. COVID-19 pandemic stressors are associated with reported increases in frequency of drunkenness among individuals with a history of alcohol use disorder. Transl. Psychiatry 13, 311 (2023).
Google Scholar
Lv, T. et al. Regional variation and temporal trend of primary biliary cholangitis epidemiology: a systematic review and meta-analysis. J. Gastroenterol. Hepatol. 36, 1423–1434 (2021).
Google Scholar
Tanaka, A. & Takikawa, H. Geoepidemiology of primary sclerosing cholangitis: a critical review. J. Autoimmun. 46, 35–40 (2013).
Google Scholar
Liang, H. et al. Incidence, prevalence, and natural history of primary sclerosing cholangitis in the United Kingdom. Medicine (Baltimore) 96, e7116 (2017).
Google Scholar
Boonstra, K. et al. Population-based epidemiology, malignancy risk, and outcome of primary sclerosing cholangitis. Hepatology 58, 2045–2055 (2013).
Google Scholar
Lv, T. et al. Systematic review and meta-analysis on the incidence and prevalence of autoimmune hepatitis in Asian, European, and American population. J. Gastroenterol. Hepatol. 34, 1676–1684 (2019).
Google Scholar
Dinse, G. E. et al. Increasing prevalence of antinuclear antibodies in the United States. Arthritis Rheumatol. 72, 1026–1035 (2020).
Google Scholar
Webb, G. J., Ryan, R. P., Marshall, T. P. & Hirschfield, G. M. The epidemiology of UK autoimmune liver disease varies with geographic latitude. Clin. Gastroenterol. Hepatol. 19, 2587–2596 (2021).
Google Scholar
Danielsson Borssén, Å. et al. Epidemiology and causes of death in a Swedish cohort of patients with autoimmune hepatitis. Scand. J. Gastroenterol. 52, 1022–1028 (2017).
Google Scholar
Tanaka, A. et al. Increase trend in the prevalence and male-to-female ratio of primary biliary cholangitis, autoimmune hepatitis, and primary sclerosing cholangitis in Japan. Hepatol. Res 49, 881–889 (2019).
Google Scholar
Kim, B. H. et al. Population-based prevalence, incidence, and disease burden of autoimmune hepatitis in South Korea. PLoS ONE 12, e0182391 (2017).
Google Scholar
Xie, J. J. & Wu, Z. Y. Wilson’s disease in China. Neurosci. Bull. 33, 323–330 (2017).
Google Scholar
Lo, C. & Bandmann, O. Epidemiology and introduction to the clinical presentation of Wilson disease. Handb. Clin. Neurol. 142, 7–17 (2017).
Google Scholar
European Association for Study of Liver. EASL Clinical Practice Guidelines: Wilson’s disease. J. Hepatol. 56, 671-685 (2012).
Coffey, A. J. et al. A genetic study of Wilson’s disease in the United Kingdom. Brain 136, 1476–1487 (2013).
Google Scholar
Hamesch, K. et al. Liver fibrosis and metabolic alterations in adults with alpha-1-antitrypsin deficiency caused by the Pi*ZZ mutation. Gastroenterology 157, 705–719.e718 (2019).
Google Scholar
Flemming, J. A. et al. Incidence of cirrhosis in young birth cohorts in Canada from 1997 to 2016: a retrospective population-based study. Lancet Gastroenterol. Hepatol. 4, 217–226 (2019).
Google Scholar
Ala, A. et al. Wilson’s disease. Lancet 369, 397–408 (2007).
Google Scholar
Moon, A. M., Singal, A. G. & Tapper, E. B. Contemporary epidemiology of chronic liver disease and cirrhosis. Clin. Gastroenterol. Hepatol. 18, 2650–2666 (2020).
Google Scholar
Gu, W. et al. Trends and the course of liver cirrhosis and its complications in Germany: nationwide population-based study (2005 to 2018). Lancet Reg. Health Eur. 12, 100240 (2022).
Google Scholar
Enomoto, H. et al. Transition in the etiology of liver cirrhosis in Japan: a nationwide survey. J. Gastroenterol. 55, 353–362 (2020).
Google Scholar
Jang, W. Y. et al. Changes in characteristics of patients with liver cirrhosis visiting a tertiary hospital over 15 years: a retrospective multi-center Study in Korea. J. Korean Med. Sci. 35, e233 (2020).
Google Scholar
Vento, S., Dzudzor, B., Cainelli, F. & Tachi, K. Liver cirrhosis in sub-Saharan Africa: neglected, yet important. Lancet Glob. Health 6, e1060–e1061 (2018).
Google Scholar
Zhang, C. H. et al. Changing epidemiology of hepatocellular carcinoma in Asia. Liver Int. 42, 2029–2041 (2022).
Google Scholar
Singal, A. G., Lampertico, P. & Nahon, P. Epidemiology and surveillance for hepatocellular carcinoma: New trends. J. Hepatol. 72, 250–261 (2020).
Google Scholar
Konyn, P., Ahmed, A. & Kim, D. Current epidemiology in hepatocellular carcinoma. Expert Rev. Gastroenterol. Hepatol. 15, 1295–1307 (2021).
Google Scholar
Rich, N. E., Yopp, A. C., Singal, A. G. & Murphy, C. C. Hepatocellular carcinoma incidence is decreasing among younger adults in the United States. Clin. Gastroenterol. Hepatol. 18, 242–248.e245 (2020).
Google Scholar
Toh, M. R. et al. Global epidemiology and genetics of hepatocellular carcinoma. Gastroenterology 164, 766–782 (2023).
Google Scholar
Fanning, G. C., Zoulim, F., Hou, J. & Bertoletti, A. Therapeutic strategies for hepatitis B virus infection: towards a cure. Nat. Rev. Drug Discov. 18, 827–844 (2019).
Google Scholar
Suarez, A. A. R. & Zoulim, F. Opportunities and challenges for hepatitis B cure. eGastroenterology 1, e100021 (2023).
Google Scholar
Lemoine, M. & Thursz, M. R. Battlefield against hepatitis B infection and HCC in Africa. J. Hepatol. 66, 645–654 (2017).
Google Scholar
Mathurin, P. & Bataller, R. Trends in the management and burden of alcoholic liver disease. J. Hepatol. 62, S38–S46 (2015).
Google Scholar
Danpanichkul, P. et al. Incidence of liver cancer in young adults according to the Global Burden of Disease database 2019. Hepatology 80, 828–843 (2024).
Meijer, N. et al. The aflatoxin situation in Africa: Systematic literature review. Compr. Rev. Food Sci. Food Saf. 20, 2286–2304 (2021).
Google Scholar
Bertuccio, P. et al. A comparison of trends in mortality from primary liver cancer and intrahepatic cholangiocarcinoma in Europe. Ann. Oncol. 24, 1667–1674 (2013).
Google Scholar
Beal, E. W. et al. Cohort contributions to trends in the incidence and mortality of intrahepatic cholangiocarcinoma. Hepatobiliary Surg. Nutr. 7, 270–276 (2018).
Google Scholar
Saha, S. K., Zhu, A. X., Fuchs, C. S. & Brooks, G. A. Forty-year trends in cholangiocarcinoma incidence in the U.S.: intrahepatic disease on the rise. Oncologist 21, 594–599 (2016).
Google Scholar
Florio, A. A. et al. Global trends in intrahepatic and extrahepatic cholangiocarcinoma incidence from 1993 to 2012. Cancer 126, 2666–2678 (2020).
Google Scholar
Khan, S. A., Tavolari, S. & Brandi, G. Cholangiocarcinoma: epidemiology and risk factors. Liver Int. 39, 19–31 (2019).
Google Scholar
Ouyang, G. et al. The global, regional, and national burden of gallbladder and biliary tract cancer and its attributable risk factors in 195 countries and territories, 1990 to 2017: a systematic analysis for the Global Burden of Disease Study 2017. Cancer 127, 2238–2250 (2021).
Google Scholar
European Association for the Study of the Liver. EASL Clinical Practice Guidelines on nutrition in chronic liver disease. J. Hepatol. 70, 172–193 (2019).
Hansen, L. et al. Symptom classes in decompensated liver disease. Clin. Gastroenterol. Hepatol. 20, 2551–2557.e2551 (2022).
Google Scholar
Kaya, E. & Yilmaz, Y. Metabolic-associated Fatty Liver Disease (MAFLD): a multi-systemic disease beyond the liver. J. Clin. Transl. Hepatol. 10, 329–338 (2022).
Google Scholar
Hernandez-Tejero, M., Clemente-Sanchez, A. & Bataller, R. Spectrum, screening, and diagnosis of alcohol-related liver disease. J. Clin. Exp. Hepatol. 13, 75–87 (2023).
Google Scholar
Ortega-Alonso, A., Stephens, C., Lucena, M. I. & Andrade, R. J. Case characterization, clinical features and risk factors in drug-induced liver injury. Int. J. Mol. Sci. 17 (2016).
Mazzaro, C. et al. A review on extrahepatic manifestations of chronic Hepatitis C virus infection and the impact of direct-acting antiviral therapy. Viruses. 13 (2021).
Terziroli Beretta-Piccoli, B., Mieli-Vergani, G. & Vergani, D. Autoimmmune hepatitis. Cell Mol. Immunol. 19, 158–176 (2022).
Google Scholar
Younossi, Z. M. et al. Diagnosis and management of primary biliary cholangitis. Am. J. Gastroenterol. 114, 48–63 (2019).
Google Scholar
Li, H. et al. Plasma lipidomics of primary biliary cholangitis and its comparison with Sjögren’s syndrome. Front. Immunol. 14, 1124443 (2023).
Google Scholar
Barberio, B. et al. Prevalence of primary sclerosing cholangitis in patients with inflammatory bowel disease: a systematic review and meta-analysis. Gastroenterology 161, 1865–1877 (2021).
Google Scholar
Assis, D. N. & Bowlus, C. L. Recent advances in the management of primary sclerosing cholangitis. Clin. Gastroenterol. Hepatol. 21, 2065–2075 (2023).
Google Scholar
van Munster, K. N., Bergquist, A. & Ponsioen, C. Y. Inflammatory bowel disease and primary sclerosing cholangitis: one disease or two? J. Hepatol. 80, 155–168 (2024).
Google Scholar
Eslam, M., Sanyal, A. J. & George, J. MAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease. Gastroenterology 158, 1999–2014.e1991 (2020).
Google Scholar
Gómez-Medina, C., Melo, L., Martí-Aguado, D. & Bataller, R. Subclinical versus advanced forms of alcohol-related liver disease: Need for early detection. Clin. Mol. Hepatol. 29, 1–15 (2023).
Google Scholar
Członkowska, A. et al. Wilson disease. Nat. Rev. Dis. Prim. 4, 21 (2018).
Google Scholar
Wu, T. et al. Liver disease progression in patients with alpha-1 antitrypsin deficiency and protease inhibitor ZZ genotype with or without lung disease. Aliment Pharm. Ther. 58, 1075–1085 (2023).
Google Scholar
D’Amico, G., Bernardi, M. & Angeli, P. Towards a new definition of decompensated cirrhosis. J. Hepatol. 76, 202–207 (2022).
Google Scholar
Rose, C. F. et al. Hepatic encephalopathy: novel insights into classification, pathophysiology and therapy. J. Hepatol. 73, 1526–1547 (2020).
Google Scholar
Llovet, J. M. et al. Nonalcoholic steatohepatitis-related hepatocellular carcinoma: pathogenesis and treatment. Nat. Rev. Gastroenterol. Hepatol. 20, 487–503 (2023).
Google Scholar
Clouston, A. D. et al. Severe acute liver disease in adults: contemporary role of histopathology. Histopathology 85, 549–561 (2024).
Ahmad, J. et al. Value of liver biopsy in the diagnosis of drug-induced liver injury. J. Hepatol. 76, 1070–1078 (2022).
Google Scholar
Brown, G. T. & Kleiner, D. E. Histopathology of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Metabolism 65, 1080–1086 (2016).
Google Scholar
Portmann, B. & Zen, Y. Inflammatory disease of the bile ducts-cholangiopathies: liver biopsy challenge and clinicopathological correlation. Histopathology 60, 236–248 (2012).
Google Scholar
Floreani, A., Gabbia, D. & De Martin, S. Current perspectives on the molecular and clinical relationships between primary biliary cholangitis and hepatocellular carcinoma. Int. J. Mol. Sci. 25 (2024).
de Boer, Y. S. et al. Assessment of the histopathological key features in autoimmune hepatitis. Histopathology 66, 351–362 (2015).
Google Scholar
Cardoso, A. C., Figueiredo-Mendes, C., Villela-Nogueira, C. A. & Marcellin, P. Staging fibrosis in chronic viral hepatitis. Viruses. 14 (2022).
Loomba, R. et al. Review article: new developments in biomarkers and clinical drug development in alpha-1 antitrypsin deficiency-related liver disease. Aliment Pharm. Ther. 59, 1183–1195 (2024).
Google Scholar
Leone, V. et al. Liver Inflammation and Hepatobiliary Cancers. Trends Cancer 7, 606–623 (2021).
Google Scholar
European Association for the Study of the Liver. EASL Clinical Practice Guidelines on non-invasive tests for evaluation of liver disease severity and prognosis—2021 update. J. Hepatol. 75, 659–689 (2021).
Yuen, M. F. et al. Hepatitis B virus infection. Nat. Rev. Dis. Prim. 4, 18035 (2018).
Google Scholar
Negro, F. & Lok, A. S. Hepatitis D: a review. Jama 330, 2376–2387 (2023).
Google Scholar
Ma, Z., de Man, R. A., Kamar, N. & Pan, Q. Chronic hepatitis E: advancing research and patient care. J. Hepatol. 77, 1109–1123 (2022).
Google Scholar
Colley, D. G., Bustinduy, A. L., Secor, W. E. & King, C. H. Human schistosomiasis. Lancet 383, 2253–2264 (2014).
Google Scholar
McManus, D. P., Zhang, W., Li, J. & Bartley, P. B. Echinococcosis. Lancet 362, 1295–1304 (2003).
Google Scholar
Zhang, C. et al. Involvement of TIGIT in natural killer cell exhaustion and immune escape in patients and mouse model with liver Echinococcus multilocularis Infection. Hepatology 74, 3376–3393 (2021).
Google Scholar
Morán, P. et al. Amoebiasis: advances in diagnosis, treatment, immunology features and the interaction with the intestinal ecosystem. Int. J. Mol. Sci. 24 (2023).
Eslam, M. et al. A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement. J. Hepatol. 73, 202–209 (2020).
Google Scholar
Miao, L. et al. Current status and future trends of the global burden of MASLD. Trends Endocrinol. Metab. 35, 697–707 (2024).
Nasereldin, D. S. et al. Association of metabolic health phenotypes, obesity, and hepatocellular carcinoma risk. Dig. Liver Dis. 54, 964–972 (2022).
Google Scholar
Kwon, Y. M. et al. Association of nonalcoholic fatty liver disease with components of metabolic syndrome according to body mass index in Korean adults. Am. J. Gastroenterol. 107, 1852–1858 (2012).
Google Scholar
Arab, J. P. et al. Bile acids and nonalcoholic fatty liver disease: Molecular insights and therapeutic perspectives. Hepatology 65, 350–362 (2017).
Google Scholar
Friedman, S. L., Neuschwander-Tetri, B. A., Rinella, M. & Sanyal, A. J. Mechanisms of NAFLD development and therapeutic strategies. Nat. Med. 24, 908–922 (2018).
Google Scholar
Tilg, H., Adolph, T. E., Dudek, M. & Knolle, P. Non-alcoholic fatty liver disease: the interplay between metabolism, microbes and immunity. Nat. Metab. 3, 1596–1607 (2021).
Google Scholar
Feng, G. et al. Recompensation in cirrhosis: unravelling the evolving natural history of nonalcoholic fatty liver disease. Nat. Rev. Gastroenterol. Hepatol. 21, 46–56 (2024).
Google Scholar
Xu, X. et al. Targeted therapeutics and novel signaling pathways in non-alcohol-associated fatty liver/steatohepatitis (NAFL/NASH). Signal Transduct. Target Ther. 7, 287 (2022).
Google Scholar
Chalasani, N. et al. Features and outcomes of 899 patients with drug-induced liver injury: the DILIN prospective study. Gastroenterology 148, 1340–1352.e1347 (2015).
Google Scholar
Li, X., Tang, J. & Mao, Y. Incidence and risk factors of drug-induced liver injury. Liver Int. 42, 1999–2014 (2022).
Google Scholar
Andrade, R. J. et al. Drug-induced liver injury. Nat. Rev. Dis. Prim. 5, 58 (2019).
Google Scholar
Stephens, C., Lucena, M. I. & Andrade, R. J. Genetic risk factors in the development of idiosyncratic drug-induced liver injury. Expert Opin. Drug Metab. Toxicol. 17, 153–169 (2021).
Google Scholar
Mackowiak, B., Fu, Y., Maccioni, L. & Gao, B. Alcohol-associated liver disease. J. Clin. Invest. 134 (2024).
Kamper-Jørgensen, M., Grønbaek, M., Tolstrup, J. & Becker, U. Alcohol and cirrhosis: dose-response or threshold effect? J. Hepatol. 41, 25–30 (2004).
Google Scholar
Inan-Eroglu, E. et al. Joint associations of adiposity and alcohol consumption with liver disease-related morbidity and mortality risk: findings from the UK Biobank. Eur. J. Clin. Nutr. 76, 74–83 (2022).
Google Scholar
Sinn, D. H. et al. Alcohol intake and mortality in patients with chronic viral hepatitis: a nationwide cohort study. Am. J. Gastroenterol. 116, 329–335 (2021).
Google Scholar
Chang, B. et al. Prevalence and prediction of hepatocellular carcinoma in alcohol-associated liver disease: a retrospective study of 136 571 patients with chronic liver diseases. eGastroenterology 2, e100036 (2024).
Google Scholar
Panetta, M., Brightmore, A. & Waring, W. S. Delayed onset of liver injury after intentional chloroform overdose: a case report and literature review. Acute Med. 18, 192–196 (2019).
Google Scholar
Santos, O. et al. Acute liver failure due to white phosphorus ingestion. Ann. Hepatol. 8, 162–165 (2009).
Google Scholar
Scholten, D., Trebicka, J., Liedtke, C. & Weiskirchen, R. The carbon tetrachloride model in mice. Lab Anim. 49, 4–11 (2015).
Google Scholar
Cave, M. et al. Toxicant-associated steatohepatitis in vinyl chloride workers. Hepatology 51, 474–481 (2010).
Google Scholar
Wu, Y. et al. Association between per- and poly-fluoroalkyl substances and nonalcoholic fatty liver disease: a nested case-control study in northwest China. Environ. Pollut. 350, 123937 (2024).
Google Scholar
Liu, Y., Galani Yamdeu, J. H., Gong, Y. Y. & Orfila, C. A review of postharvest approaches to reduce fungal and mycotoxin contamination of foods. Compr. Rev. Food Sci. Food Saf. 19, 1521–1560 (2020).
Google Scholar
Zabaleta, N., Hommel, M., Salas, D. & Gonzalez-Aseguinolaza, G. Genetic-based approaches to inherited metabolic liver diseases. Hum. Gene Ther. 30, 1190–1203 (2019).
Google Scholar
Pietrangelo, A. Hereditary hemochromatosis: pathogenesis, diagnosis, and treatment. Gastroenterology 139, 393–408 (2010). 408.e391-392.
Google Scholar
Feder, J. N. et al. A novel MHC class I-like gene is mutated in patients with hereditary haemochromatosis. Nat. Genet. 13, 399–408 (1996).
Google Scholar
Nemeth, E. et al. Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science 306, 2090–2093 (2004).
Google Scholar
Aschemeyer, S. et al. Structure-function analysis of ferroportin defines the binding site and an alternative mechanism of action of hepcidin. Blood 131, 899–910 (2018).
Google Scholar
Chen, L., Min, J. & Wang, F. Copper homeostasis and cuproptosis in health and disease. Signal Transduct. Target Ther. 7, 378 (2022).
Google Scholar
Greene, C. M. et al. α1-Antitrypsin deficiency. Nat. Rev. Dis. Prim. 2, 16051 (2016).
Google Scholar
Lomas, D. A., Hurst, J. R. & Gooptu, B. Update on alpha-1 antitrypsin deficiency: new therapies. J. Hepatol. 65, 413–424 (2016).
Google Scholar
Rehwinkel, J. & Gack, M. U. RIG-I-like receptors: their regulation and roles in RNA sensing. Nat. Rev. Immunol. 20, 537–551 (2020).
Google Scholar
Onomoto, K., Onoguchi, K. & Yoneyama, M. Regulation of RIG-I-like receptor-mediated signaling: interaction between host and viral factors. Cell Mol. Immunol. 18, 539–555 (2021).
Google Scholar
Ivashkiv, L. B. & Donlin, L. T. Regulation of type I interferon responses. Nat. Rev. Immunol. 14, 36–49 (2014).
Google Scholar
Żeromski, J. et al. Pattern recognition receptors: significance of expression in the liver. Arch. Immunol. Ther. Exp. (Warsz.) 68, 29 (2020).
Google Scholar
Li, Y. et al. Activation of endogenous type I IFN signaling contributes to persistent HCV infection. Rev. Med. Virol. 24, 332–342 (2014).
Google Scholar
Asahina, Y. et al. Association of gene expression involving innate immunity and genetic variation in interleukin 28B with antiviral response. Hepatology 55, 20–29 (2012).
Google Scholar
Dixit, U. et al. Staufen1 promotes HCV replication by inhibiting protein kinase R and transporting viral RNA to the site of translation and replication in the cells. Nucleic Acids Res. 44, 5271–5287 (2016).
Google Scholar
Shi, X. et al. MxA is a positive regulator of type I IFN signaling in HCV infection. J. Med Virol. 89, 2173–2180 (2017).
Google Scholar
Li, C. Z. et al. Polymorphism of OAS-1 determines liver fibrosis progression in hepatitis C by reduced ability to inhibit viral replication. Liver Int. 29, 1413–1421 (2009).
Google Scholar
Li, X. D. et al. Hepatitis C virus protease NS3/4A cleaves mitochondrial antiviral signaling protein off the mitochondria to evade innate immunity. Proc. Natl Acad. Sci. USA 102, 17717–17722 (2005).
Google Scholar
Liang, Y. et al. Antiviral suppression vs restoration of RIG-I signaling by hepatitis C protease and polymerase inhibitors. Gastroenterology 135, 1710–1718.e1712 (2008).
Google Scholar
Song, H. et al. TRIM25 inhibits HBV replication by promoting HBx degradation and the RIG-I-mediated pgRNA recognition. Chin. Med. J. (Engl.) 136, 799–806 (2023).
Google Scholar
Sato, S. et al. The RNA sensor RIG-I dually functions as an innate sensor and direct antiviral factor for hepatitis B virus. Immunity 42, 123–132 (2015).
Google Scholar
Lee, S. et al. Suppression of hepatitis B virus through therapeutic activation of RIG-I and IRF3 signaling in hepatocytes. iScience 24, 101969 (2021).
Google Scholar
Jiang, J. & Tang, H. Mechanism of inhibiting type I interferon induction by hepatitis B virus X protein. Protein Cell 1, 1106–1117 (2010).
Google Scholar
Giersch, K. et al. Strain-specific responsiveness of hepatitis D virus to interferon-alpha treatment. JHEP Rep. 5, 100673 (2023).
Google Scholar
Devhare, P. B., Desai, S. & Lole, K. S. Innate immune responses in human hepatocyte-derived cell lines alter genotype 1 hepatitis E virus replication efficiencies. Sci. Rep. 6, 26827 (2016).
Google Scholar
Sung, P. S. et al. CXCL10 is produced in hepatitis A virus-infected cells in an IRF3-dependent but IFN-independent manner. Sci. Rep. 7, 6387 (2017).
Google Scholar
Sun, L. et al. Cyclic GMP-AMP synthase is a cytosolic DNA sensor that activates the type I interferon pathway. Science 339, 786–791 (2013).
Google Scholar
Chen, Q., Sun, L. & Chen, Z. J. Regulation and function of the cGAS-STING pathway of cytosolic DNA sensing. Nat. Immunol. 17, 1142–1149 (2016).
Google Scholar
Kuipery, A., Gehring, A. J. & Isogawa, M. Mechanisms of HBV immune evasion. Antivir. Res. 179, 104816 (2020).
Google Scholar
He, J. et al. Inhibition of hepatitis B virus replication by activation of the cGAS-STING pathway. J. Gen. Virol. 97, 3368–3378 (2016).
Google Scholar
Dansako, H. et al. The cyclic GMP-AMP synthetase-STING signaling pathway is required for both the innate immune response against HBV and the suppression of HBV assembly. FEBS J. 283, 144–156 (2016).
Google Scholar
Ding, Q. et al. Hepatitis C virus NS4B blocks the interaction of STING and TBK1 to evade host innate immunity. J. Hepatol. 59, 52–58 (2013).
Google Scholar
Chen, L. et al. Loss of Sam50 in hepatocytes induces cardiolipin-dependent mitochondrial membrane remodeling to trigger mtDNA release and liver injury. Hepatology 76, 1389–1408 (2022).
Google Scholar
Liu, Z. et al. XBP1 deficiency promotes hepatocyte pyroptosis by impairing mitophagy to activate mtDNA-cGAS-STING signaling in macrophages during acute liver injury. Redox Biol. 52, 102305 (2022).
Google Scholar
Li, Y. et al. Ginsenoside Rd inhibited ferroptosis to alleviate CCl(4)-induced acute liver injury in mice via cGAS/STING Pathway. Am. J. Chin. Med. 51, 91–105 (2023).
Google Scholar
Ma, X. et al. Loss of hepatic DRP1 exacerbates alcoholic hepatitis by inducing megamitochondria and mitochondrial maladaptation. Hepatology 77, 159–175 (2023).
Google Scholar
Lin, Z. et al. RING finger protein 13 protects against nonalcoholic steatohepatitis by targeting STING-relayed signaling pathways. Nat. Commun. 14, 6635 (2023).
Google Scholar
Liu, K. et al. Lipotoxicity-induced STING1 activation stimulates MTORC1 and restricts hepatic lipophagy. Autophagy 18, 860–876 (2022).
Google Scholar
Huang, X. et al. Macrophage SCAP contributes to metaflammation and lean NAFLD by activating STING-NF-κB signaling pathway. Cell Mol. Gastroenterol. Hepatol. 14, 1–26 (2022).
Google Scholar
Steinberg, G. R. & Hardie, D. G. New insights into activation and function of the AMPK. Nat. Rev. Mol. Cell Biol. 24, 255–272 (2023).
Google Scholar
Xu, X. et al. Nuclear UHRF1 is a gate-keeper of cellular AMPK activity and function. Cell Res. 32, 54–71 (2022).
Google Scholar
Herzig, S. & Shaw, R. J. AMPK: guardian of metabolism and mitochondrial homeostasis. Nat. Rev. Mol. Cell Biol. 19, 121–135 (2018).
Google Scholar
Göransson, O., Kopietz, F. & Rider, M. H. Metabolic control by AMPK in white adipose tissue. Trends Endocrinol. Metab. 34, 704–717 (2023).
Google Scholar
Zhao, L. et al. CD36 palmitoylation disrupts free fatty acid metabolism and promotes tissue inflammation in non-alcoholic steatohepatitis. J. Hepatol. 69, 705–717 (2018).
Google Scholar
Lu, X. et al. AMPK protects against alcohol-induced liver injury through UQCRC2 to up-regulate mitophagy. Autophagy 17, 3622–3643 (2021).
Google Scholar
Castaño, D. et al. Cardiotrophin-1 eliminates hepatic steatosis in obese mice by mechanisms involving AMPK activation. J. Hepatol. 60, 1017–1025 (2014).
Google Scholar
Cai, Y. et al. Disruption of adenosine 2A receptor exacerbates NAFLD through increasing inflammatory responses and SREBP1c activity. Hepatology 68, 48–61 (2018).
Google Scholar
Allard, B. et al. Adenosine A2A receptor is a tumor suppressor of NASH-associated hepatocellular carcinoma. Cell Rep. Med. 4, 101188 (2023).
Google Scholar
Zhu, W. et al. Activation of hepatic adenosine A1 receptor ameliorates MASH via inhibiting SREBPs maturation. Cell Rep. Med. 5, 101477 (2024).
Google Scholar
Wan, J. et al. Gastrodin improves nonalcoholic fatty liver disease through activation of the adenosine monophosphate-activated protein kinase signaling pathway. Hepatology 74, 3074–3090 (2021).
Google Scholar
O’Neill, H. M. et al. AMPK phosphorylation of ACC2 is required for skeletal muscle fatty acid oxidation and insulin sensitivity in mice. Diabetologia 57, 1693–1702 (2014).
Google Scholar
Shearn, C. T. et al. Identification of 5’ AMP-activated kinase as a target of reactive aldehydes during chronic ingestion of high concentrations of ethanol. J. Biol. Chem. 289, 15449–15462 (2014).
Google Scholar
Handa, P. et al. Reduced adiponectin signaling due to weight gain results in nonalcoholic steatohepatitis through impaired mitochondrial biogenesis. Hepatology 60, 133–145 (2014).
Google Scholar
Zhu, Z. et al. Involvement of insulin resistance in the protective effect of metformin against alcoholic liver injury. Alcohol Clin. Exp. Res 38, 1510–1519 (2014).
Google Scholar
Chen, M. et al. Cdo1-Camkk2-AMPK axis confers the protective effects of exercise against NAFLD in mice. Nat. Commun. 14, 8391 (2023).
Google Scholar
Qiu, B. et al. MKP1 promotes nonalcoholic steatohepatitis by suppressing AMPK activity through LKB1 nuclear retention. Nat. Commun. 14, 5405 (2023).
Google Scholar
You, Y. et al. SNX10 mediates alcohol-induced liver injury and steatosis by regulating the activation of chaperone-mediated autophagy. J. Hepatol. 69, 129–141 (2018).
Google Scholar
Shen, B. et al. Aucubin inhibited lipid accumulation and oxidative stress via Nrf2/HO-1 and AMPK signalling pathways. J. Cell Mol. Med. 23, 4063–4075 (2019).
Google Scholar
Zhang, Y. et al. Exercise and Metformin intervention prevents lipotoxicity-induced hepatocyte apoptosis by alleviating oxidative and ER stress and activating the AMPK/Nrf2/HO-1 signaling pathway in db/db mice. Oxid. Med Cell Longev. 2022, 2297268 (2022).
Google Scholar
Peng, W. et al. Zanthoxylum bungeanum amides ameliorates nonalcoholic fatty liver via regulating gut microbiota and activating AMPK/Nrf2 signaling. J. Ethnopharmacol. 318, 116848 (2024).
Google Scholar
Zhao, P. et al. An AMPK-caspase-6 axis controls liver damage in nonalcoholic steatohepatitis. Science 367, 652–660 (2020).
Google Scholar
You, Y. et al. FNDC3B protects steatosis and ferroptosis via the AMPK pathway in alcoholic fatty liver disease. Free Radic. Biol. Med 193, 808–819 (2022).
Google Scholar
Zheng, L. et al. Prognostic significance of AMPK activation and therapeutic effects of metformin in hepatocellular carcinoma. Clin. Cancer Res. 19, 5372–5380 (2013).
Google Scholar
Cheng, L. et al. Hepatic mitochondrial NAD + transporter SLC25A47 activates AMPKα mediating lipid metabolism and tumorigenesis. Hepatology 78, 1828–1842 (2023).
Google Scholar
Canovas, B. & Nebreda, A. R. Diversity and versatility of p38 kinase signalling in health and disease. Nat. Rev. Mol. Cell Biol. 22, 346–366 (2021).
Google Scholar
Bahar, M. E., Kim, H. J. & Kim, D. R. Targeting the RAS/RAF/MAPK pathway for cancer therapy: from mechanism to clinical studies. Signal Transduct. Target Ther. 8, 455 (2023).
Google Scholar
Wang, L. et al. Tripartite motif 16 ameliorates nonalcoholic steatohepatitis by promoting the degradation of phospho-TAK1. Cell Metab. 33, 1372–1388.e1377 (2021).
Google Scholar
Che, Z. et al. Melatonin alleviates alcoholic liver disease via EGFR-BRG1-TERT axis regulation. Acta Pharm. Sin. B 13, 100–112 (2023).
Google Scholar
Fang, Z. et al. Narirutin activates TFEB (transcription factor EB) to protect against Acetaminophen-induced liver injury by targeting PPP3/calcineurin. Autophagy 19, 2240–2256 (2023).
Google Scholar
Kim, H. J., Han, Y. H., Kim, J. Y. & Lee, M. O. RORα Enhances Lysosomal Acidification and Autophagic Flux in the Hepatocytes. Hepatol. Commun. 5, 2121–2138 (2021).
Google Scholar
Inami, Y. et al. Hepatic steatosis inhibits autophagic proteolysis via impairment of autophagosomal acidification and cathepsin expression. Biochem Biophys. Res Commun. 412, 618–625 (2011).
Google Scholar
Lee, A. Y. et al. Dihydroceramide is a key metabolite that regulates autophagy and promotes fibrosis in hepatic steatosis model. Biochem. Biophys. Res Commun. 494, 460–469 (2017).
Google Scholar
Zeng, J. et al. Restoration of lysosomal acidification rescues autophagy and metabolic dysfunction in non-alcoholic fatty liver disease. Nat. Commun. 14, 2573 (2023).
Google Scholar
Lo, C. H. et al. Acidic nanoparticles restore lysosomal acidification and rescue metabolic dysfunction in pancreatic β-cells under lipotoxic conditions. ACS Nano 18, 15452–15467 (2024).
Google Scholar
Xu, W. et al. O-GlcNAc transferase promotes fatty liver-associated liver cancer through inducing palmitic acid and activating endoplasmic reticulum stress. J. Hepatol. 67, 310–320 (2017).
Google Scholar
Zhang, X. et al. Macrophage p38α promotes nutritional steatohepatitis through M1 polarization. J. Hepatol. 71, 163–174 (2019).
Google Scholar
Liu, J. et al. Deficiency of p38α in macrophage ameliorates d-galactosamine/TNF-α-induced acute liver injury in mice. FEBS J. 284, 4200–4215 (2017).
Google Scholar
Cai, B. et al. Macrophage MerTK promotes liver fibrosis in nonalcoholic steatohepatitis. Cell Metab. 31, 406–421.e407 (2020).
Google Scholar
Zhang, Z. et al. ANGPTL8 accelerates liver fibrosis mediated by HFD-induced inflammatory activity via LILRB2/ERK signaling pathways. J. Adv. Res. 47, 41–56 (2023).
Google Scholar
Thoen, L. F. et al. A role for autophagy during hepatic stellate cell activation. J. Hepatol. 55, 1353–1360 (2011).
Google Scholar
He, Y. et al. Targeting PI3K/Akt signal transduction for cancer therapy. Signal Transduct. Target Ther. 6, 425 (2021).
Google Scholar
Jung, K. et al. Farnesoid X receptor activation impairs liver progenitor cell-mediated liver regeneration via the PTEN-PI3K-AKT-mTOR axis in zebrafish. Hepatology 74, 397–410 (2021).
Google Scholar
Zhang, Z. et al. Exosomes derived from human adipose mesenchymal stem cells ameliorate hepatic fibrosis by inhibiting PI3K/Akt/mTOR pathway and remodeling choline metabolism. J. Nanobiotechnol. 21, 29 (2023).
Google Scholar
Jackson, L. N. et al. PI3K/Akt activation is critical for early hepatic regeneration after partial hepatectomy. Am. J. Physiol. Gastrointest. Liver Physiol. 294, G1401–1410 (2008).
Google Scholar
Nechemia-Arbely, Y. et al. Early hepatocyte DNA synthetic response posthepatectomy is modulated by IL-6 trans-signaling and PI3K/AKT activation. J. Hepatol. 54, 922–929 (2011).
Google Scholar
Ye, Q. et al. Deficiency of gluconeogenic enzyme PCK1 promotes metabolic-associated fatty liver disease through PI3K/AKT/PDGF axis activation in male mice. Nat. Commun. 14, 1402 (2023).
Google Scholar
Zhang, L., Zhou, F. & ten Dijke, P. Signaling interplay between transforming growth factor-β receptor and PI3K/AKT pathways in cancer. Trends Biochem. Sci. 38, 612–620 (2013).
Google Scholar
Yuan, M. et al. DC-SIGN-LEF1/TCF1-miR-185 feedback loop promotes colorectal cancer invasion and metastasis. Cell Death Differ. 27, 379–395 (2020).
Google Scholar
Zhao, C., Wang, B., Liu, E. & Zhang, Z. Loss of PTEN expression is associated with PI3K pathway-dependent metabolic reprogramming in hepatocellular carcinoma. Cell Commun. Signal 18, 131 (2020).
Google Scholar
Luo, Y. et al. PI3K/AKT1 signaling pathway mediates sinomenine-induced hepatocellular carcinoma cells apoptosis: an in vitro and in vivo study. Biol. Pharm. Bull. 45, 614–624 (2022).
Google Scholar
Philips, R. L. et al. The JAK-STAT pathway at 30: Much learned, much more to do. Cell 185, 3857–3876 (2022).
Google Scholar
Xue, C. et al. Evolving cognition of the JAK-STAT signaling pathway: autoimmune disorders and cancer. Signal Transduct. Target Ther. 8, 204 (2023).
Google Scholar
Rocca, S. et al. Targeting few to help hundreds: JAK, MAPK and ROCK pathways as druggable targets in atypical chronic myeloid leukemia. Mol. Cancer 17, 40 (2018).
Google Scholar
Asuri, S. et al. Primary biliary cholangitis in British Columbia First Nations: clinical features and discovery of novel genetic susceptibility loci. Liver Int 38, 940–948 (2018).
Google Scholar
Cordell, H. J. et al. International genome-wide meta-analysis identifies new primary biliary cirrhosis risk loci and targetable pathogenic pathways. Nat. Commun. 6, 8019 (2015).
Google Scholar
Gordon, S. C. et al. Baricitinib and primary biliary cholangitis. J. Transl. Autoimmun. 4, 100107 (2021).
Google Scholar
Shao, T. et al. Treatment with a JAK1/2 inhibitor ameliorates murine autoimmune cholangitis induced by IFN overexpression. Cell Mol. Immunol. 19, 1130–1140 (2022).
Google Scholar
Schoggins, J. W. Interferon-stimulated genes: what do they all do? Annu Rev. Virol. 6, 567–584 (2019).
Google Scholar
Makjaroen, J. et al. Comprehensive proteomics identification of IFN-λ3-regulated antiviral proteins in HBV-transfected cells. Mol. Cell Proteom. 17, 2197–2215 (2018).
Google Scholar
Chen, Y. et al. ISG12a inhibits HCV replication and potentiates the anti-HCV activity of IFN-α through activation of the Jak/STAT signaling pathway independent of autophagy and apoptosis. Virus Res 227, 231–239 (2017).
Google Scholar
Zhao, J., Qi, Y. F. & Yu, Y. R. STAT3: a key regulator in liver fibrosis. Ann. Hepatol. 21, 100224 (2021).
Google Scholar
Wang, F. et al. Activated natural killer cell promotes nonalcoholic steatohepatitis through mediating JAK/STAT pathway. Cell Mol. Gastroenterol. Hepatol. 13, 257–274 (2022).
Google Scholar
Grohmann, M. et al. Obesity drives STAT-1-dependent NASH and STAT-3-dependent HCC. Cell 175, 1289–1306.e1220 (2018).
Google Scholar
Liu, J. et al. Wnt/β-catenin signalling: function, biological mechanisms, and therapeutic opportunities. Signal Transduct. Target Ther. 7, 3 (2022).
Google Scholar
Pez, F. et al. Wnt signaling and hepatocarcinogenesis: molecular targets for the development of innovative anticancer drugs. J. Hepatol. 59, 1107–1117 (2013).
Google Scholar
Rebouissou, S. et al. Genotype-phenotype correlation of CTNNB1 mutations reveals different ß-catenin activity associated with liver tumor progression. Hepatology 64, 2047–2061 (2016).
Google Scholar
Laurent-Puig, P. et al. Genetic alterations associated with hepatocellular carcinomas define distinct pathways of hepatocarcinogenesis. Gastroenterology 120, 1763–1773 (2001).
Google Scholar
Sun, Y. et al. Integrated multi-omics profiling to dissect the spatiotemporal evolution of metastatic hepatocellular carcinoma. Cancer Cell 42, 135–156.e117 (2024).
Google Scholar
Kim, M. et al. Functional interaction between Wnt3 and Frizzled-7 leads to activation of the Wnt/beta-catenin signaling pathway in hepatocellular carcinoma cells. J. Hepatol. 48, 780–791 (2008).
Google Scholar
Cadoret, A. et al. Hepatomegaly in transgenic mice expressing an oncogenic form of beta-catenin. Cancer Res. 61, 3245–3249 (2001).
Google Scholar
Nejak-Bowen, K. N. et al. Accelerated liver regeneration and hepatocarcinogenesis in mice overexpressing serine-45 mutant beta-catenin. Hepatology 51, 1603–1613 (2010).
Google Scholar
Rignall, B., Braeuning, A., Buchmann, A. & Schwarz, M. Tumor formation in liver of conditional β-catenin-deficient mice exposed to a diethylnitrosamine/phenobarbital tumor promotion regimen. Carcinogenesis 32, 52–57 (2011).
Google Scholar
Liang, Y. et al. β-catenin deficiency in hepatocytes aggravates hepatocarcinogenesis driven by oncogenic β-catenin and MET. Hepatology 67, 1807–1822 (2018).
Google Scholar
Boulter, L. et al. WNT signaling drives cholangiocarcinoma growth and can be pharmacologically inhibited. J. Clin. Invest. 125, 1269–1285 (2015).
Google Scholar
Chen, Q. et al. Circular RNA ACTN4 promotes intrahepatic cholangiocarcinoma progression by recruiting YBX1 to initiate FZD7 transcription. J. Hepatol. 76, 135–147 (2022).
Google Scholar
Massagué, J. TGFβ signalling in context. Nat. Rev. Mol. Cell Biol. 13, 616–630 (2012).
Google Scholar
Deng, Z. et al. TGF-β signaling in health, disease, and therapeutics. Signal Transduct. Target Ther. 9, 61 (2024).
Google Scholar
Henderson, N. C. et al. Targeting of αv integrin identifies a core molecular pathway that regulates fibrosis in several organs. Nat. Med. 19, 1617–1624 (2013).
Google Scholar
Tahashi, Y. et al. Differential regulation of TGF-beta signal in hepatic stellate cells between acute and chronic rat liver injury. Hepatology 35, 49–61 (2002).
Google Scholar
Gorham, J. D. Transforming growth factor-beta1, Th1 responses, and autoimmune liver disease. Transfusion 45, 51s–59s (2005).
Google Scholar
Chida, T. et al. Critical role of CREBH-mediated induction of transforming growth factor β2 by hepatitis C virus infection in fibrogenic responses in hepatic stellate cells. Hepatology 66, 1430–1443 (2017).
Google Scholar
He, W. et al. Identifying a distinct fibrosis subset of NAFLD via molecular profiling and the involvement of profibrotic macrophages. J. Transl. Med. 21, 448 (2023).
Google Scholar
Lurje, I., Gaisa, N. T., Weiskirchen, R. & Tacke, F. Mechanisms of organ fibrosis: emerging concepts and implications for novel treatment strategies. Mol. Asp. Med. 92, 101191 (2023).
Google Scholar
Meng, L. et al. NPRC deletion attenuates cardiac fibrosis in diabetic mice by activating PKA/PKG and inhibiting TGF-β1/Smad pathways. Sci. Adv. 9, eadd4222 (2023).
Google Scholar
Sharma, A. et al. Lipopolysaccharide reverses hepatic stellate cell activation through modulation of cMyb, small mothers against decapentaplegic, and CCAAT/enhancer-binding protein C/EBP transcription factors. Hepatology 72, 1800–1818 (2020).
Google Scholar
Song, Y. et al. Tyrosine kinase receptor B attenuates liver fibrosis by inhibiting TGF-β/SMAD signaling. Hepatology 78, 1433–1447 (2023).
Google Scholar
Russo, I. et al. Protective effects of activated myofibroblasts in the pressure-overloaded myocardium are mediated through smad-dependent activation of a matrix-preserving program. Circ. Res. 124, 1214–1227 (2019).
Google Scholar
Busnadiego, O. et al. LOXL4 is induced by transforming growth factor β1 through Smad and JunB/Fra2 and contributes to vascular matrix remodeling. Mol. Cell Biol. 33, 2388–2401 (2013).
Google Scholar
Zhang, J. et al. Sirt6 alleviated liver fibrosis by deacetylating conserved lysine 54 on Smad2 in hepatic stellate cells. Hepatology 73, 1140–1157 (2021).
Google Scholar
Yu, J. et al. Kindlin-2 regulates hepatic stellate cells activation and liver fibrogenesis. Cell Death Discov. 4, 34 (2018).
Google Scholar
Le Pabic, H. et al. Involvement of the serine/threonine p70S6 kinase in TGF-beta1-induced ADAM12 expression in cultured human hepatic stellate cells. J. Hepatol. 43, 1038–1044 (2005).
Google Scholar
Gong, J., Tu, W., Liu, J. & Tian, D. Hepatocytes: a key role in liver inflammation. Front Immunol. 13, 1083780 (2022).
Google Scholar
Loft, A. et al. A macrophage-hepatocyte glucocorticoid receptor axis coordinates fasting ketogenesis. Cell Metab. 34, 473–486.e479 (2022).
Google Scholar
Gehrke, N. et al. Hepatocyte-specific deletion of IL1-RI attenuates liver injury by blocking IL-1 driven autoinflammation. J. Hepatol. 68, 986–995 (2018).
Google Scholar
Dong, X. et al. Ursodesoxycholic acid alleviates liver fibrosis via proregeneration by activation of the ID1-WNT2/HGF signaling pathway. Clin. Transl. Med. 11, e296 (2021).
Google Scholar
Kaffe, E. et al. Humanized mouse liver reveals endothelial control of essential hepatic metabolic functions. Cell 186, 3793–3809.e3726 (2023).
Google Scholar
Banales, J. M. et al. Cholangiocyte pathobiology. Nat. Rev. Gastroenterol. Hepatol. 16, 269–281 (2019).
Google Scholar
Raven, A. et al. Cholangiocytes act as facultative liver stem cells during impaired hepatocyte regeneration. Nature 547, 350–354 (2017).
Google Scholar
Pinto, C., Giordano, D. M., Maroni, L. & Marzioni, M. Role of inflammation and proinflammatory cytokines in cholangiocyte pathophysiology. Biochim. Biophys. Acta Mol. Basis Dis. 1864, 1270–1278 (2018).
Google Scholar
Strazzabosco, M. et al. Pathophysiologic implications of innate immunity and autoinflammation in the biliary epithelium. Biochim Biophys. Acta Mol. Basis Dis. 1864, 1374–1379 (2018).
Google Scholar
Gao, J. et al. Angiocrine signaling in sinusoidal homeostasis and liver diseases. J. Hepatol. 81, 543–561 (2024).
Gao, J. et al. Endothelial p300 promotes portal hypertension and hepatic fibrosis through C-C motif chemokine ligand 2-mediated angiocrine signaling. Hepatology 73, 2468–2483 (2021).
Google Scholar
Greuter, T. et al. Mechanotransduction-induced glycolysis epigenetically regulates a CXCL1-dominant angiocrine signaling program in liver sinusoidal endothelial cells in vitro and in vivo. J. Hepatol. 77, 723–734 (2022).
Google Scholar
Hilscher, M. B. et al. Mechanical stretch increases expression of CXCL1 in liver sinusoidal endothelial cells to recruit neutrophils, generate sinusoidal microthombi, and promote portal hypertension. Gastroenterology 157, 193–209.e199 (2019).
Google Scholar
Desroches-Castan, A. et al. Bone morphogenetic protein 9 is a paracrine factor controlling liver sinusoidal endothelial cell fenestration and protecting against hepatic fibrosis. Hepatology 70, 1392–1408 (2019).
Google Scholar
Gaitantzi, H. et al. BMP-9 Modulates the Hepatic Responses to LPS. Cells 9 (2020).
Schmid, C. D. et al. ALK1 controls hepatic vessel formation, angiodiversity, and angiocrine functions in hereditary hemorrhagic telangiectasia of the liver. Hepatology 77, 1211–1227 (2023).
Google Scholar
Tsuchida, T. & Friedman, S. L. Mechanisms of hepatic stellate cell activation. Nat. Rev. Gastroenterol. Hepatol. 14, 397–411 (2017).
Google Scholar
Mederacke, I. et al. Fate tracing reveals hepatic stellate cells as dominant contributors to liver fibrosis independent of its aetiology. Nat. Commun. 4, 2823 (2013).
Google Scholar
Iwaisako, K. et al. Origin of myofibroblasts in the fibrotic liver in mice. Proc. Natl Acad. Sci. USA 111, E3297–E3305 (2014).
Google Scholar
Poisson, J. et al. Liver sinusoidal endothelial cells: physiology and role in liver diseases. J. Hepatol. 66, 212–227 (2017).
Google Scholar
Colucci, S. et al. Liver sinusoidal endothelial cells suppress bone morphogenetic protein 2 production in response to TGFβ pathway activation. Hepatology 74, 2186–2200 (2021).
Google Scholar
Meyer, J. et al. Platelet interactions with liver sinusoidal endothelial cells and hepatic stellate cells lead to hepatocyte proliferation. Cells 9 (2020).
Wang, Q. et al. Role of XBP1 in regulating the progression of non-alcoholic steatohepatitis. J. Hepatol. 77, 312–325 (2022).
Google Scholar
Xiao, Y. et al. STING mediates hepatocyte pyroptosis in liver fibrosis by epigenetically activating the NLRP3 inflammasome. Redox Biol. 62, 102691 (2023).
Google Scholar
Wen, Y., Lambrecht, J., Ju, C. & Tacke, F. Hepatic macrophages in liver homeostasis and diseases-diversity, plasticity and therapeutic opportunities. Cell Mol. Immunol. 18, 45–56 (2021).
Google Scholar
Blériot, C. et al. A subset of Kupffer cells regulates metabolism through the expression of CD36. Immunity 54, 2101–2116.e2106 (2021).
Google Scholar
Tran, S. et al. Impaired Kupffer cell self-renewal alters the liver response to lipid overload during non-alcoholic steatohepatitis. Immunity 53, 627–640.e625 (2020).
Google Scholar
Krenkel, O. et al. Myeloid cells in liver and bone marrow acquire a functionally distinct inflammatory phenotype during obesity-related steatohepatitis. Gut 69, 551–563 (2020).
Google Scholar
Sun, X. et al. Transcriptional switch of hepatocytes initiates macrophage recruitment and T-cell suppression in endotoxemia. J. Hepatol. 77, 436–452 (2022).
Google Scholar
Feng, D. et al. Monocyte-derived macrophages orchestrate multiple cell-type interactions to repair necrotic liver lesions in disease models. J. Clin. Invest. 133 (2023).
Ma, H. Y. et al. IL-17 signaling in steatotic hepatocytes and macrophages promotes hepatocellular carcinoma in alcohol-related liver disease. J. Hepatol. 72, 946–959 (2020).
Google Scholar
Xiong, X. et al. Landscape of intercellular crosstalk in healthy and NASH liver revealed by single-cell secretome gene analysis. Mol. Cell 75, 644–660.e645 (2019).
Google Scholar
Ramachandran, P. et al. Differential Ly-6C expression identifies the recruited macrophage phenotype, which orchestrates the regression of murine liver fibrosis. Proc. Natl Acad. Sci. USA 109, E3186–E3195 (2012).
Google Scholar
Moreno-Lanceta, A. et al. RNF41 orchestrates macrophage-driven fibrosis resolution and hepatic regeneration. Sci. Transl. Med. 15, eabq6225 (2023).
Google Scholar
Ficht, X. & Iannacone, M. Immune surveillance of the liver by T cells. Sci. Immunol. 5 (2020).
Mieli-Vergani, G. et al. Autoimmune hepatitis. Nat. Rev. Dis. Prim. 4, 18017 (2018).
Google Scholar
Hardtke-Wolenski, M. et al. The influence of genetic predisposition and autoimmune hepatitis inducing antigens in disease development. J. Autoimmun. 78, 39–45 (2017).
Google Scholar
Iannacone, M. & Guidotti, L. G. Immunobiology and pathogenesis of hepatitis B virus infection. Nat. Rev. Immunol. 22, 19–32 (2022).
Google Scholar
Binder, B. & Thimme, R. CD4+ T cell responses in human viral infection: lessons from hepatitis C. J. Clin. Invest 130, 595–597 (2020).
Google Scholar
Liu, K., Wang, F. S. & Xu, R. Neutrophils in liver diseases: pathogenesis and therapeutic targets. Cell Mol. Immunol. 18, 38–44 (2021).
Google Scholar
Liu, M. et al. Super enhancer regulation of cytokine-induced chemokine production in alcoholic hepatitis. Nat. Commun. 12, 4560 (2021).
Google Scholar
Huang, H. et al. Damage-associated molecular pattern-activated neutrophil extracellular trap exacerbates sterile inflammatory liver injury. Hepatology 62, 600–614 (2015).
Google Scholar
Ariño, S. et al. Ductular reaction-associated neutrophils promote biliary epithelium proliferation in chronic liver disease. J. Hepatol. 79, 1025–1036 (2023).
Google Scholar
Yan, M. et al. Gut liver brain axis in diseases: the implications for therapeutic interventions. Signal Transduct. Target Ther. 8, 443 (2023).
Google Scholar
Mouries, J. et al. Microbiota-driven gut vascular barrier disruption is a prerequisite for non-alcoholic steatohepatitis development. J. Hepatol. 71, 1216–1228 (2019).
Google Scholar
Shao, T. et al. Intestinal HIF-1α deletion exacerbates alcoholic liver disease by inducing intestinal dysbiosis and barrier dysfunction. J. Hepatol. 69, 886–895 (2018).
Google Scholar
Loomba, R. et al. Gut microbiome-based metagenomic signature for non-invasive detection of advanced fibrosis in human nonalcoholic fatty liver disease. Cell Metab. 25, 1054–1062.e1055 (2017).
Google Scholar
Rabot, S. et al. Germ-free C57BL/6J mice are resistant to high-fat-diet-induced insulin resistance and have altered cholesterol metabolism. FASEB J. 24, 4948–4959 (2010).
Google Scholar
Le Roy, T. et al. Intestinal microbiota determines development of non-alcoholic fatty liver disease in mice. Gut 62, 1787–1794 (2013).
Google Scholar
Steensels, S. et al. Acyl-coenzyme a thioesterase 9 traffics mitochondrial short-chain fatty acids toward de novo lipogenesis and glucose production in the liver. Hepatology 72, 857–872 (2020).
Google Scholar
Niu, Y. et al. Blautia coccoides is a newly identified bacterium increased by leucine deprivation and has a novel function in improving metabolic disorders. Adv. Sci. (Weinh.) 11, e2309255 (2024).
Google Scholar
Song, Q. et al. Bifidobacterium pseudolongum-generated acetate suppresses non-alcoholic fatty liver disease-associated hepatocellular carcinoma. J. Hepatol. 79, 1352–1365 (2023).
Google Scholar
Park, B. S. et al. The structural basis of lipopolysaccharide recognition by the TLR4-MD-2 complex. Nature 458, 1191–1195 (2009).
Google Scholar
Carpino, G. et al. Increased liver localization of lipopolysaccharides in human and experimental NAFLD. Hepatology 72, 470–485 (2020).
Google Scholar
Wang, S. et al. Hyperoside attenuates non-alcoholic fatty liver disease in rats via cholesterol metabolism and bile acid metabolism. J. Adv. Res. 34, 109–122 (2021).
Google Scholar
Modica, S. et al. Selective activation of nuclear bile acid receptor FXR in the intestine protects mice against cholestasis. Gastroenterology 142, 355–365.e351-354 (2012).
Google Scholar
Clifford, B. L. et al. FXR activation protects against NAFLD via bile-acid-dependent reductions in lipid absorption. Cell Metab. 33, 1671–1684.e1674 (2021).
Google Scholar
Liu, S. et al. Melatonin mitigates aflatoxin B1-induced liver injury via modulation of gut microbiota/intestinal FXR/liver TLR4 signaling axis in mice. J. Pineal Res. 73, e12812 (2022).
Google Scholar
Cheon, S. Y. & Song, J. The association between hepatic encephalopathy and diabetic encephalopathy: the brain-liver axis. Int. J. Mol. Sci. 22 (2021).
Görg, B. et al. O-GlcNAcylation-dependent upregulation of HO1 triggers ammonia-induced oxidative stress and senescence in hepatic encephalopathy. J. Hepatol. 71, 930–941 (2019).
Google Scholar
Lama, A. et al. Palmitoylethanolamide dampens neuroinflammation and anxiety-like behavior in obese mice. Brain Behav. Immun. 102, 110–123 (2022).
Google Scholar
Asimakidou, E., Saipuljumri, E. N., Lo, C. H. & Zeng, J. Role of metabolic dysfunction and inflammation along the liver-brain axis in animal models with obesity-induced neurodegeneration. Neural Regen. Res. 20, 1069–1076 (2025).
Google Scholar
Fallahzadeh, M. A. & Rahimi, R. S. Hepatic encephalopathy: current and emerging treatment modalities. Clin. Gastroenterol. Hepatol. 20, S9–s19 (2022).
Google Scholar
Patterson, T. T. et al. Complex feed-forward and feedback mechanisms underlie the relationship between traumatic brain injury and the gut-microbiota-brain axis. Shock 52, 318–325 (2019).
Google Scholar
Hackl, M. T. et al. Brain leptin reduces liver lipids by increasing hepatic triglyceride secretion and lowering lipogenesis. Nat. Commun. 10, 2717 (2019).
Google Scholar
Metz, M. et al. Leptin increases hepatic triglyceride export via a vagal mechanism in humans. Cell Metab. 34, 1719–1731.e1715 (2022).
Google Scholar
Saeidinejad, M. et al. Novel therapeutic approaches in treatment of acute-on-chronic liver failure. Semin. Liver Dis. 43, 429–445 (2023).
Google Scholar
Duwaerts, C. C. & Maher, J. J. Macronutrients and the adipose-liver axis in obesity and fatty liver. Cell Mol. Gastroenterol. Hepatol. 7, 749–761 (2019).
Google Scholar
Wu, X. et al. Recent advances in understanding of pathogenesis of alcohol-associated liver disease. Annu. Rev. Pathol. 18, 411–438 (2023).
Google Scholar
Xu, A. et al. The fat-derived hormone adiponectin alleviates alcoholic and nonalcoholic fatty liver diseases in mice. J. Clin. Invest. 112, 91–100 (2003).
Google Scholar
Polyzos, S. A. et al. Circulating leptin in non-alcoholic fatty liver disease: a systematic review and meta-analysis. Diabetologia 59, 30–43 (2016).
Google Scholar
Lee, E., Korf, H. & Vidal-Puig, A. An adipocentric perspective on the development and progression of non-alcoholic fatty liver disease. J. Hepatol. 78, 1048–1062 (2023).
Google Scholar
Zarei, M. et al. Targeting FGF21 for the treatment of nonalcoholic steatohepatitis. Trends Pharm. Sci. 41, 199–208 (2020).
Google Scholar
Holland, W. L. et al. An FGF21-adiponectin-ceramide axis controls energy expenditure and insulin action in mice. Cell Metab. 17, 790–797 (2013).
Google Scholar
Xiao, G., Yang, J. & Yan, L. Comparison of diagnostic accuracy of aspartate aminotransferase to platelet ratio index and fibrosis-4 index for detecting liver fibrosis in adult patients with chronic hepatitis B virus infection: a systemic review and meta-analysis. Hepatology 61, 292–302 (2015).
Google Scholar
Terrault, N. A. et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology 67, 1560–1599 (2018).
Google Scholar
Ghany, M. G. & Morgan, T. R. Hepatitis C Guidance 2019 Update: American Association for the Study of Liver Diseases-Infectious Diseases Society of America Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection. Hepatology 71, 686–721 (2020).
Google Scholar
Muhoza, P. et al. Routine vaccination coverage—worldwide, 2020. MMWR Morb. Mortal. Wkly. Rep. 70, 1495–1500 (2021).
Google Scholar
European Association for the Study of the Liver. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J. Hepatol. 67, 370–398 (2017).
Tseng, C. H. et al. Hepatocellular carcinoma incidence with tenofovir versus entecavir in chronic hepatitis B: a systematic review and meta-analysis. Lancet Gastroenterol. Hepatol. 5, 1039–1052 (2020).
Google Scholar
Martinez, M. G. et al. Covalently closed circular DNA: The ultimate therapeutic target for curing HBV infections. J. Hepatol. 75, 706–717 (2021).
Google Scholar
Yip, T. C. et al. HBsAg seroclearance further reduces hepatocellular carcinoma risk after complete viral suppression with nucleos(t)ide analogues. J. Hepatol. 70, 361–370 (2019).
Google Scholar
European Association for the Study of the Liver. EASL recommendations on treatment of hepatitis C: Final update of the series(☆). J. Hepatol. 73, 1170–1218 (2020).
European Association for the Study of the Liver. EASL Clinical Practice Guidelines on hepatitis delta virus. J.Hepatol. 79, 433–460 (2023).
European Association for the Study of the Liver. EASL Clinical Practice Guidelines on hepatitis E virus infection. J. Hepatol. 68, 1256–1271 (2018).
Koch, D. G. et al. The Natural History of Severe Acute Liver Injury. Am. J. Gastroenterol. 112, 1389–1396 (2017).
Google Scholar
Palmer, M. et al. Consensus guidelines: best practices for detection, assessment and management of suspected acute drug-induced liver injury occurring during clinical trials in adults with chronic cholestatic liver disease. Aliment Pharm. Ther. 51, 90–109 (2020).
Google Scholar
Kim, W. R., Flamm, S. L., Di Bisceglie, A. M. & Bodenheimer, H. C. Serum activity of alanine aminotransferase (ALT) as an indicator of health and disease. Hepatology 47, 1363–1370 (2008).
Google Scholar
Stravitz, R. T. et al. Bleeding complications in acute liver failure. Hepatology 67, 1931–1942 (2018).
Google Scholar
Björnsson, H. K. & Björnsson, E. S. Drug-induced liver injury: Pathogenesis, epidemiology, clinical features, and practical management. Eur. J. Intern. Med. 97, 26–31 (2022).
Google Scholar
European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Drug-induced liver injury. J. Hepatol. 70, 1222–1261 (2019).
Stravitz, R. T. et al. Future directions in acute liver failure. Hepatology 78, 1266–1289 (2023).
Google Scholar
Fontana, R. J. et al. AASLD practice guidance on drug, herbal, and dietary supplement-induced liver injury. Hepatology 77, 1036–1065 (2023).
Google Scholar
Li, M. et al. Pharmacotherapies for drug-induced liver injury: a current literature review. Front Pharm. 12, 806249 (2021).
Google Scholar
Moosa, M. S. et al. A randomized controlled trial of intravenous n-acetylcysteine in the management of anti-tuberculosis drug-induced liver injury. Clin. Infect. Dis. 73, e3377–e3383 (2021).
Google Scholar
Flamm, S. L., Yang, Y. X., Singh, S. & Falck-Ytter, Y. T. American gastroenterological association institute guidelines for the diagnosis and management of acute liver failure. Gastroenterology 152, 644–647 (2017).
Google Scholar
Hwang, S. et al. Novel treatment of acute and acute-on-chronic liver failure: Interleukin-22. Liver Int. (2023).
Arab, J. P. et al. An open-label, dose-escalation study to assess the safety and efficacy of IL-22 agonist F-652 in patients with alcohol-associated hepatitis. Hepatology 72, 441–453 (2020).
Google Scholar
Saliba, F. et al. Artificial liver support in patients with liver failure: a modified DELPHI consensus of international experts. Intensive Care Med. 48, 1352–1367 (2022).
Google Scholar
Artru, F., Goldberg, D. & Kamath, P. S. Should patients with acute-on-chronic liver failure grade 3 receive higher priority for liver transplantation? J. Hepatol. 78, 1118–1123 (2023).
Google Scholar
Karvellas, C. J. et al. AASLD Practice Guidance on Acute-on-chronic liver failure and the management of critically ill patients with cirrhosis. Hepatology 79, 1463–1502 (2024).
Google Scholar
Wendon, J. et al. EASL Clinical Practical Guidelines on the management of acute (fulminant) liver failure. J. Hepatol. 66, 1047–1081 (2017).
Google Scholar
European Association for the Study of the Liver. EASL Clinical Practice Guidelines on acute-on-chronic liver failure. J. Hepatol. 79, 461–491 (2023).
Rinella, M. E. et al. AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease. Hepatology 77, 1797–1835 (2023).
Google Scholar
Eslam, M. et al. The Asian Pacific Association for the Study of the Liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease. Hepatol. Int. 14, 889–919 (2020).
Google Scholar
Cusi, K. et al. American Association of Clinical Endocrinology Clinical Practice Guideline for the Diagnosis and Management of Nonalcoholic Fatty Liver Disease in Primary Care and Endocrinology Clinical Settings: Co-Sponsored by the American Association for the Study of Liver Diseases (AASLD). Endocr. Pr. 28, 528–562 (2022).
Google Scholar
Younossi, Z. M., Zelber-Sagi, S., Henry, L. & Gerber, L. H. Lifestyle interventions in nonalcoholic fatty liver disease. Nat. Rev. Gastroenterol. Hepatol. 20, 708–722 (2023).
Google Scholar
Zhang, X. et al. Unhealthy lifestyle habits and physical inactivity among Asian patients with non-alcoholic fatty liver disease. Liver Int. 40, 2719–2731 (2020).
Google Scholar
Park, M. J., Kim, H., Kim, M. G. & Kim, K. Comparison of glucagon-like peptide-1 receptor agonists and thiazolidinediones on treating nonalcoholic fatty liver disease: a network meta-analysis. Clin. Mol. Hepatol. 29, 693–704 (2023).
Google Scholar
Wang, Z. et al. Response to pioglitazone in non-alcoholic fatty liver disease patients with vs. without type 2 diabetes: a meta-analysis of randomized controlled trials. Front. Endocrinol. (Lausanne) 14, 1111430 (2023).
Google Scholar
Pose, E. et al. Safety of two different doses of simvastatin plus rifaximin in decompensated cirrhosis (LIVERHOPE-SAFETY): a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Gastroenterol. Hepatol. 5, 31–41 (2020).
Google Scholar
Ramandi, A. et al. Polypill protects MAFLD patients from cardiovascular events and mortality: a prospective trial. Hepatol. Int. 17, 882–888 (2023).
Google Scholar
Harrison, S. A. et al. Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. Lancet 394, 2012–2024 (2019).
Google Scholar
Wang, G. et al. Impacts of bariatric surgery on adverse liver outcomes: a systematic review and meta-analysis. Surg. Obes. Relat. Dis. 19, 717–726 (2023).
Google Scholar
Younossi, Z. M. et al. The changing epidemiology of adult liver transplantation in the United States in 2013-2022: the dominance of metabolic dysfunction-associated steatotic liver disease and alcohol-associated liver disease. Hepatol Commun. 8 (2024).
European Association for the Study of the Liver. EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). J. Hepatol. 81, 492–542 (2024).
Singal, A. K. & Mathurin, P. Diagnosis and treatment of alcohol-associated liver disease: a review. JAMA 326, 165–176 (2021).
Google Scholar
Bataller, R., Arab, J. P. & Shah, V. H. Alcohol-associated hepatitis. N. Engl. J. Med. 387, 2436–2448 (2022).
Google Scholar
Nahon, P. et al. Assessment of liver fibrosis using transient elastography in patients with alcoholic liver disease. J. Hepatol. 49, 1062–1068 (2008).
Google Scholar
Crabb, D. W. et al. Standard definitions and common data elements for clinical trials in patients with alcoholic hepatitis: recommendation from the NIAAA Alcoholic Hepatitis Consortia. Gastroenterology 150, 785–790 (2016).
Google Scholar
European Association for the Study of the Liver. EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J. Hepatol. 64, 1388–1402 (2016).
Crabb, D. W. et al. Diagnosis and treatment of alcohol-associated liver diseases: 2019 Practice Guidance From the American Association for the Study of Liver Diseases. Hepatology 71, 306–333 (2020).
Google Scholar
Vannier, A. G. L. et al. Incidence and progression of alcohol-associated liver disease after medical therapy for alcohol use disorder. JAMA Netw. Open 5, e2213014 (2022).
Google Scholar
Mathurin, P. & Lucey, M. R. Liver transplantation in patients with alcohol-related liver disease: current status and future directions. Lancet Gastroenterol. Hepatol. 5, 507–514 (2020).
Google Scholar
European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of alcohol-related liver disease. J. Hepatol. 69, 154–181 (2018).
Wang, Q. X. et al. Clinical and histological features of autoantibody-negative autoimmune hepatitis in Chinese patients: a single center experience. J. Dig. Dis. 14, 175–180 (2013).
Google Scholar
Dahlqvist, G. et al. Large-scale characterization study of patients with antimitochondrial antibodies but nonestablished primary biliary cholangitis. Hepatology 65, 152–163 (2017).
Google Scholar
Aabakken, L. et al. Role of endoscopy in primary sclerosing cholangitis: European Society of Gastrointestinal Endoscopy (ESGE) and European Association for the Study of the Liver (EASL) Clinical Guideline. Endoscopy 49, 588–608 (2017).
Google Scholar
Kovač, J. D. & Weber, M. A. Primary Biliary Cirrhosis and Primary Sclerosing Cholangitis: an Update on MR Imaging Findings with Recent Developments. J. Gastrointestin Liver Dis. 25, 517–524 (2016).
Google Scholar
Gurung, A. et al. Histologic features of autoimmune hepatitis: a critical appraisal. Hum. Pathol. 82, 51–60 (2018).
Google Scholar
Purohit, T. & Cappell, M. S. Primary biliary cirrhosis: pathophysiology, clinical presentation and therapy. World J. Hepatol. 7, 926–941 (2015).
Google Scholar
Hennes, E. M. et al. Simplified criteria for the diagnosis of autoimmune hepatitis. Hepatology 48, 169–176 (2008).
Google Scholar
Wang, Z. et al. The management of autoimmune hepatitis patients with decompensated cirrhosis: real-world experience and a comprehensive review. Clin. Rev. Allergy Immunol. 52, 424–435 (2017).
Google Scholar
Harms, M. H. et al. Ursodeoxycholic acid therapy and liver transplant-free survival in patients with primary biliary cholangitis. J. Hepatol. 71, 357–365 (2019).
Google Scholar
Deneau, M. R. et al. Oral vancomycin, ursodeoxycholic acid, or no therapy for pediatric primary sclerosing cholangitis: a matched analysis. Hepatology 73, 1061–1073 (2021).
Google Scholar
Minaga, K., Watanabe, T., Chung, H. & Kudo, M. Autoimmune hepatitis and IgG4-related disease. World J. Gastroenterol. 25, 2308–2314 (2019).
Google Scholar
Mack, C. L. et al. Diagnosis and Management of Autoimmune Hepatitis in Adults and Children: 2019 Practice Guidance and Guidelines From the American Association for the Study of Liver Diseases. Hepatology 72, 671–722 (2020).
Google Scholar
Clinical, E. A. S. L. Practice guidelines: autoimmune hepatitis. J. Hepatol. 63, 971–1004 (2015).
Google Scholar
Konkwo, C., Chowdhury, S. & Vilarinho, S. Genetics of liver disease in adults. Hepatol. Commun. 8 (2024).
Tarnacka, B., Szeszkowski, W., Golebiowski, M. & Czlonkowska, A. MR spectroscopy in monitoring the treatment of Wilson’s disease patients. Mov. Disord. 23, 1560–1566 (2008).
Google Scholar
Brewer, G. J. et al. Oral zinc therapy for Wilson’s disease. Ann. Intern. Med. 99, 314–319 (1983).
Google Scholar
Wiggelinkhuizen, M., Tilanus, M. E., Bollen, C. W. & Houwen, R. H. Systematic review: clinical efficacy of chelator agents and zinc in the initial treatment of Wilson disease. Aliment Pharm. Ther. 29, 947–958 (2009).
Google Scholar
Schilsky, M. L. Wilson disease: diagnosis, treatment, and follow-up. Clin. Liver Dis. 21, 755–767 (2017).
Google Scholar
Schilsky, M. L. et al. A multidisciplinary approach to the diagnosis and management of Wilson disease: Executive summary of the 2022 Practice Guidance on Wilson disease from the American Association for the Study of Liver Diseases. Hepatology 77, 1428–1455 (2023).
Google Scholar
European Association for the Study of the Liver. EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis. J. Hepatol. 69, 406–460 (2018).
Pennisi, G. et al. Noninvasive assessment of liver disease severity in patients with nonalcoholic fatty liver disease (NAFLD) and type 2 diabetes. Hepatology 78, 195–211 (2023).
Google Scholar
Newsome, P. N. et al. FibroScan-AST (FAST) score for the non-invasive identification of patients with non-alcoholic steatohepatitis with significant activity and fibrosis: a prospective derivation and global validation study. Lancet Gastroenterol. Hepatol. 5, 362–373 (2020).
Google Scholar
Garcia-Tsao, G., Abraldes, J. G., Berzigotti, A. & Bosch, J. Portal hypertensive bleeding in cirrhosis: Risk stratification, diagnosis, and management: 2016 practice guidance by the American Association for the study of liver diseases. Hepatology 65, 310–335 (2017).
Google Scholar
Marcellin, P. et al. Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study. Lancet 381, 468–475 (2013).
Google Scholar
Cai, X. et al. Hydronidone for the treatment of liver fibrosis related to chronic hepatitis B: a phase 2 randomized controlled trial. Clin. Gastroenterol. Hepatol. 21, 1893–1901.e1897 (2023).
Google Scholar
Brusilovskaya, K., Königshofer, P., Schwabl, P. & Reiberger, T. Vascular targets for the treatment of portal hypertension. Semin Liver Dis. 39, 483–501 (2019).
Google Scholar
Biggins, S. W. et al. Diagnosis, evaluation, and management of ascites, spontaneous bacterial peritonitis and hepatorenal syndrome: 2021 Practice Guidance by the American Association for the Study of Liver Diseases. Hepatology 74, 1014–1048 (2021).
Google Scholar
Bai, Z. et al. Role of terlipressin in cirrhotic patients with ascites and without hepatorenal syndrome: a systematic review of current evidence. Can. J. Gastroenterol. Hepatol. 2020, 5106958 (2020).
Google Scholar
de Franchis, R. et al. Baveno VII—renewing consensus in portal hypertension. J. Hepatol. 76, 959–974 (2022).
Google Scholar
Lim, C. et al. Auxiliary liver transplantation for cirrhosis: from APOLT to RAPID: a scoping review. Ann. Surg. 275, 551–559 (2022).
Google Scholar
Rogal, S. S. et al. AASLD Practice Guidance: Palliative care and symptom-based management in decompensated cirrhosis. Hepatology 76, 819–853 (2022).
Google Scholar
Lai, J. C. et al. Malnutrition, frailty, and sarcopenia in patients with cirrhosis: 2021 Practice Guidance by the American Association for the Study of Liver Diseases. Hepatology 74, 1611–1644 (2021).
Google Scholar
Kaplan, D. E. et al. AASLD Practice Guidance on risk stratification and management of portal hypertension and varices in cirrhosis. Hepatology 79, 1180–1211 (2024).
Google Scholar
European Association for the Study of the Liver. EASL Clinical Practice Guidelines on prevention and management of bleeding and thrombosis in patients with cirrhosis. J. Hepatol. 76, 1151–1184 (2022).
Marrero, J. A. et al. Diagnosis, staging, and management of hepatocellular carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases. Hepatology 68, 723–750 (2018).
Google Scholar
Tan, C. H., Low, S. C. & Thng, C. H. APASL and AASLD consensus guidelines on imaging diagnosis of hepatocellular carcinoma: a review. Int J. Hepatol. 2011, 519783 (2011).
Google Scholar
Chang, T. S. et al. Alpha-fetoprotein measurement benefits hepatocellular carcinoma surveillance in patients with cirrhosis. Am. J. Gastroenterol. 110, 836–844 (2015).
Google Scholar
Singal, A. G. et al. International Liver Cancer Association (ILCA) white paper on biomarker development for hepatocellular carcinoma. Gastroenterology 160, 2572–2584 (2021).
Google Scholar
Reig, M. et al. BCLC strategy for prognosis prediction and treatment recommendation: the 2022 update. J. Hepatol. 76, 681–693 (2022).
Google Scholar
Singal, A. G. et al. AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma. Hepatology 78, 1922–1965 (2023).
Google Scholar
Tabrizian, P. et al. Ten-year outcomes of liver transplant and downstaging for hepatocellular carcinoma. JAMA Surg. 157, 779–788 (2022).
Google Scholar
Mehta, N. et al. Excellent outcomes of liver transplantation following down-staging of hepatocellular carcinoma to within milan criteria: a multicenter study. Clin. Gastroenterol. Hepatol. 16, 955–964 (2018).
Google Scholar
Lencioni, R. et al. Early-stage hepatocellular carcinoma in patients with cirrhosis: long-term results of percutaneous image-guided radiofrequency ablation. Radiology 234, 961–967 (2005).
Google Scholar
Vietti Violi, N. et al. Efficacy of microwave ablation versus radiofrequency ablation for the treatment of hepatocellular carcinoma in patients with chronic liver disease: a randomised controlled phase 2 trial. Lancet Gastroenterol. Hepatol. 3, 317–325 (2018).
Google Scholar
Salem, R. et al. Y90 radioembolization significantly prolongs time to progression compared with chemoembolization in patients with hepatocellular carcinoma. Gastroenterology 151, 1155–1163.e1152 (2016).
Google Scholar
Kulik, L. M. et al. Safety and efficacy of 90Y radiotherapy for hepatocellular carcinoma with and without portal vein thrombosis. Hepatology 47, 71–81 (2008).
Google Scholar
Yang, J. D. et al. A global view of hepatocellular carcinoma: trends, risk, prevention and management. Nat. Rev. Gastroenterol. Hepatol. 16, 589–604 (2019).
Google Scholar
Kudo, M. et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet 391, 1163–1173 (2018).
Google Scholar
Abou-Alfa, G. K. et al. Cabozantinib in patients with advanced and progressing hepatocellular carcinoma. N. Engl. J. Med. 379, 54–63 (2018).
Google Scholar
Zhu, A. X. et al. Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 20, 282–296 (2019).
Google Scholar
Llovet, J. M. et al. Immunotherapies for hepatocellular carcinoma. Nat. Rev. Clin. Oncol. 19, 151–172 (2022).
Google Scholar
Haber, P. K. et al. Evidence-Based Management of Hepatocellular Carcinoma: Systematic Review and Meta-analysis of Randomized Controlled Trials (2002-2020). Gastroenterology 161, 879–898 (2021).
Google Scholar
Llovet, J. M. Exploring a new pathway for biomarker-based approval of immunotherapies. Nat. Rev. Clin. Oncol. 20, 279–280 (2023).
Google Scholar
European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. J.Hepatol. 69, 182–236 (2018).
Elbahrawy, A. et al. Recent advances in protective vaccines against hepatitis viruses: a narrative review. Viruses 15 (2023).
Zakaria, H. M. et al. Steroid therapy in children with fulminant hepatitis A. J. Viral Hepat. 25, 853–859 (2018).
Google Scholar
Wiegand, J. et al. Treatment of severe, nonfulminant acute hepatitis B with lamivudine vs placebo: a prospective randomized double-blinded multicentre trial. J. Viral Hepat. 21, 744–750 (2014).
Google Scholar
Streinu-Cercel, A., Sandulescu, O., Stefan, M. & Streinu-Cercel, A. Treatment with lamivudine and entecavir in severe acute hepatitis B. Indian J. Med. Microbiol 34, 166–172 (2016).
Google Scholar
Naggie, S. et al. Ledipasvir/sofosbuvir for 8 weeks to treat acute hepatitis C virus infections in men with human immunodeficiency virus infections: sofosbuvir-containing regimens without interferon for treatment of acute HCV in HIV-1 infected individuals. Clin. Infect. Dis. 69, 514–522 (2019).
Google Scholar
Boerekamps, A. et al. Treatment of acute hepatitis C genotypes 1 and 4 with 8 weeks of grazoprevir plus elbasvir (DAHHS2): an open-label, multicentre, single-arm, phase 3b trial. Lancet Gastroenterol. Hepatol. 4, 269–277 (2019).
Google Scholar
Pischke, S. et al. Ribavirin treatment of acute and chronic hepatitis E: a single-centre experience. Liver Int. 33, 722–726 (2013).
Google Scholar
Da Cunha, T. & Wu, G. Y. Cytomegalovirus hepatitis in immunocompetent and immunocompromised hosts. J. Clin. Transl. Hepatol. 9, 106–115 (2021).
Google Scholar
Williams, R. & Riordan, S. M. Acute liver failure: established and putative hepatitis viruses and therapeutic implications. J. Gastroenterol. Hepatol. 15, G17–G25 (2000).
Google Scholar
Kumachev, A. & Wu, P. E. Drug-induced liver injury. CMAJ 193, E310 (2021).
Google Scholar
Dear, J. W. et al. A metabolomic analysis of thiol response for standard and modified N-acetyl cysteine treatment regimens in patients with acetaminophen overdose. Clin. Transl. Sci. 14, 1476–1489 (2021).
Google Scholar
Singh, S. et al. Comparative effectiveness of pharmacological interventions for severe alcoholic hepatitis: a systematic review and network meta-analysis. Gastroenterology 149, 958–970.e912 (2015).
Google Scholar
Sehrawat, T. S., Liu, M. & Shah, V. H. The knowns and unknowns of treatment for alcoholic hepatitis. Lancet Gastroenterol. Hepatol. 5, 494–506 (2020).
Google Scholar
Naveau, S. et al. A double-blind randomized controlled trial of infliximab associated with prednisolone in acute alcoholic hepatitis. Hepatology 39, 1390–1397 (2004).
Google Scholar
Sarin, S. K., Pande, A. & Schnabl, B. Microbiome as a therapeutic target in alcohol-related liver disease. J. Hepatol. 70, 260–272 (2019).
Google Scholar
Yuen, M. F. et al. Safety and efficacy of vebicorvir in virologically suppressed patients with chronic hepatitis B virus infection. J. Hepatol. 77, 642–652 (2022).
Google Scholar
Byun, K. S. et al. Tenofovir alafenamide for drug-resistant hepatitis b: a randomized trial for switching from tenofovir disoproxil fumarate. Clin. Gastroenterol. Hepatol. 20, 427–437.e425 (2022).
Google Scholar
Salimzadeh, L. et al. PD-1 blockade partially recovers dysfunctional virus-specific B cells in chronic hepatitis B infection. J. Clin. Invest 128, 4573–4587 (2018).
Google Scholar
Yuen, M. F. et al. RNA interference therapy with ARC-520 results in prolonged hepatitis B surface antigen response in patients with chronic hepatitis B infection. Hepatology 72, 19–31 (2020).
Google Scholar
Rohde, M. D. et al. No association between DAA treatment for HCV infection and herpes zoster infection in analysis of data from 37 clinical trials. Clin. Gastroenterol. Hepatol. 19, 1670–1678 (2021).
Google Scholar
Poordad, F. et al. Glecaprevir and pibrentasvir for 12 weeks for hepatitis C virus genotype 1 infection and prior direct-acting antiviral treatment. Hepatology 66, 389–397 (2017).
Google Scholar
Wedemeyer, H. et al. Safety and efficacy of bulevirtide in combination with tenofovir disoproxil fumarate in patients with hepatitis B virus and hepatitis D virus coinfection (MYR202): a multicentre, randomised, parallel-group, open-label, phase 2 trial. Lancet Infect. Dis. 23, 117–129 (2023).
Google Scholar
Wedemeyer, H. et al. Peginterferon alfa-2a plus tenofovir disoproxil fumarate for hepatitis D (HIDIT-II): a randomised, placebo controlled, phase 2 trial. Lancet Infect. Dis. 19, 275–286 (2019).
Google Scholar
Lang, S. & Schnabl, B. Microbiota and fatty liver disease-the known, the unknown, and the future. Cell Host Microbe 28, 233–244 (2020).
Google Scholar
Chu, H. et al. The Candida albicans exotoxin candidalysin promotes alcohol-associated liver disease. J. Hepatol. 72, 391–400 (2020).
Google Scholar
Louvet, A. et al. Corticosteroids reduce risk of death within 28 days for patients with severe alcoholic hepatitis, compared with pentoxifylline or placebo-a meta-analysis of individual data from controlled trials. Gastroenterology 155, 458–468.e458 (2018).
Google Scholar
Moreno, C. et al. Intensive enteral nutrition is ineffective for patients with severe alcoholic hepatitis treated with corticosteroids. Gastroenterology 150, 903–910.e908 (2016).
Google Scholar
Szabo, G. et al. IL-1 receptor antagonist plus pentoxifylline and zinc for severe alcohol-associated hepatitis. Hepatology 76, 1058–1068 (2022).
Google Scholar
He, Y. et al. Immunopathobiology and therapeutic targets related to cytokines in liver diseases. Cell Mol. Immunol. 18, 18–37 (2021).
Google Scholar
Teng, M. L. et al. Global incidence and prevalence of nonalcoholic fatty liver disease. Clin. Mol. Hepatol. 29, S32–s42 (2023).
Google Scholar
Gawrieh, S. et al. Saroglitazar, a PPAR-α/γ agonist, for treatment of NAFLD: a randomized controlled double-blind phase 2 trial. Hepatology 74, 1809–1824 (2021).
Google Scholar
Keam, S. J. Resmetirom: first Approval. Drugs 84, 729–735 (2024).
Díaz-González, Á. et al. Budesonide as first-line treatment in patients with autoimmune hepatitis seems inferior to standard predniso(lo)ne administration. Hepatology 77, 1095–1105 (2023).
Google Scholar
Snijders, R. et al. An open-label randomised-controlled trial of azathioprine vs. mycophenolate mofetil for the induction of remission in treatment-naive autoimmune hepatitis. J. Hepatol. 80, 576–585 (2024).
Google Scholar
Tonin, F. & Arends, I. Latest development in the synthesis of ursodeoxycholic acid (UDCA): a critical review. Beilstein J. Org. Chem. 14, 470–483 (2018).
Google Scholar
Kowdley, K. V. et al. A randomized, placebo-controlled, phase II study of obeticholic acid for primary sclerosing cholangitis. J. Hepatol. 73, 94–101 (2020).
Google Scholar
Rinella, M. E. et al. Non-invasive evaluation of response to obeticholic acid in patients with NASH: Results from the REGENERATE study. J. Hepatol. 76, 536–548 (2022).
Google Scholar
Abdelmalek, M. F. et al. Pegbelfermin in patients with nonalcoholic steatohepatitis and compensated cirrhosis (FALCON 2): a randomized phase 2b study. Clin. Gastroenterol. Hepatol. 22, 113–123.e119 (2024).
Google Scholar
Rinella, M. E. et al. A randomized, double-blind, placebo-controlled trial of aldafermin in patients with NASH and compensated cirrhosis. Hepatology 79, 674–689 (2024).
Google Scholar
Shi, M. et al. Mesenchymal stem cell therapy in decompensated liver cirrhosis: a long-term follow-up analysis of the randomized controlled clinical trial. Hepatol. Int. 15, 1431–1441 (2021).
Google Scholar
Wang, H. et al. Meta-analysis on last ten years of clinical injection of bone marrow-derived and umbilical cord MSC to reverse cirrhosis or rescue patients with acute-on-chronic liver failure. Stem Cell Res. Ther. 14, 267 (2023).
Google Scholar
Zwirner, S. et al. First-in-class MKK4 inhibitors enhance liver regeneration and prevent liver failure. Cell 187, 1666–1684.e1626 (2024).
Google Scholar
Alshamsi, F. et al. Extracorporeal liver support in patients with liver failure: a systematic review and meta-analysis of randomized trials. Intensive Care Med. 46, 1–16 (2020).
Google Scholar
Jin, Y. et al. Stem cell-derived hepatocyte therapy using versatile biomimetic nanozyme incorporated nanofiber-reinforced decellularized extracellular matrix hydrogels for the treatment of acute liver failure. Bioact. Mater. 28, 112–131 (2023).
Google Scholar
Qin, S. et al. Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study. Lancet 402, 1133–1146 (2023).
Google Scholar
Wang, K. et al. Adjuvant sintilimab in resected high-risk hepatocellular carcinoma: a randomized, controlled, phase 2 trial. Nat. Med 30, 708–715 (2024).
Google Scholar
Peng, Z. et al. Lenvatinib combined with transarterial chemoembolization as first-line treatment for advanced hepatocellular carcinoma: a phase III, randomized clinical trial (LAUNCH). J. Clin. Oncol. 41, 117–127 (2023).
Google Scholar
Yarchoan, M. et al. Personalized neoantigen vaccine and pembrolizumab in advanced hepatocellular carcinoma: a phase 1/2 trial. Nat. Med. 30, 1044–1053 (2024).
Google Scholar
Qin, S. et al. Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial. Lancet 402, 1835–1847 (2023).
Google Scholar
Díaz, L. A. et al. Impact of public health policies on alcohol-associated liver disease in Latin America: an ecological multinational study. Hepatology 74, 2478–2490 (2021).
Google Scholar
Wong, V. W. et al. Noninvasive biomarkers in NAFLD and NASH—current progress and future promise. Nat. Rev. Gastroenterol. Hepatol. 15, 461–478 (2018).
Google Scholar
Harrison, S. A. et al. Challenges and opportunities in NASH drug development. Nat. Med 29, 562–573 (2023).
Google Scholar
Henderson, N. C. et al. Galectin-3 regulates myofibroblast activation and hepatic fibrosis. Proc. Natl Acad. Sci. USA 103, 5060–5065 (2006).
Google Scholar
Chalasani, N. et al. Effects of belapectin, an inhibitor of galectin-3, in patients with nonalcoholic steatohepatitis with cirrhosis and portal hypertension. Gastroenterology 158, 1334–1345.e1335 (2020).
Google Scholar
Havelaar, A. H. et al. World Health Organization global estimates and regional comparisons of the burden of foodborne disease in 2010. PLoS Med. 12, e1001923 (2015).
Google Scholar
Gozlan, Y. et al. Ongoing hepatitis A among men who have sex with men (MSM) linked to outbreaks in Europe in Tel Aviv area, Israel, December 2016–June 2017. Euro Surveill. 22 (2017).
Hofmeister, M. G. et al. Hepatitis A person-to-person outbreaks: epidemiology, morbidity burden, and factors associated with hospitalization-multiple states, 2016-2019. J. Infect. Dis. 223, 426–434 (2021).
Google Scholar
Foster, M. A. et al. Widespread Hepatitis A outbreaks associated with person-to-person transmission—United States, 2016-2020. MMWR Morb. Mortal. Wkly. Rep. 71, 1229–1234 (2022).
Google Scholar
Zaaijer, H. L. No artifact, hepatitis E is emerging. Hepatology 62, 654 (2015).
Google Scholar
Schweitzer, A. et al. Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013. Lancet 386, 1546–1555 (2015).
Google Scholar
Eaton, J. E. et al. Pathogenesis of primary sclerosing cholangitis and advances in diagnosis and management. Gastroenterology 145, 521–536 (2013).
Google Scholar
Bambha, K. et al. Incidence, clinical spectrum, and outcomes of primary sclerosing cholangitis in a United States community. Gastroenterology 125, 1364–1369 (2003).
Google Scholar
Sandahl, T. D. et al. The prevalence of Wilson’s disease: an update. Hepatology 71, 722–732 (2020).
Google Scholar
Beyzaei, Z., Mehrzadeh, A., Hashemi, N. & Geramizadeh, B. The mutation spectrum and ethnic distribution of Wilson disease, a review. Mol. Genet. Metab. Rep. 38, 101034 (2024).
Google Scholar
Ovchinnikova, E. V., Garbuz, M. M., Ovchinnikova, A. A. & Kumeiko, V. V. Epidemiology of Wilson’s disease and pathogenic variants of the ATP7B gene leading to diversified protein disfunctions. Int. J. Mol. Sci. 25 (2024).
Blanco, I. et al. Alpha-1 antitrypsin Pi*Z gene frequency and Pi*ZZ genotype numbers worldwide: an update. Int. J. Chron. Obstruct Pulmon. Dis. 12, 561–569 (2017).
Google Scholar
Beste, L. A. et al. Trends in burden of cirrhosis and hepatocellular carcinoma by underlying liver disease in US veterans, 2001-2013. Gastroenterology 149, 1471–1482.e1475 (2015).
Google Scholar
Nakanishi, T. et al. The undiagnosed disease burden associated with alpha-1 antitrypsin deficiency genotypes. Eur. Respir. J. 56 (2020).
Ashenhurst, J. R. et al. Prevalence of alpha-1 antitrypsin deficiency, self-reported behavior change, and health care engagement among direct-to-consumer recipients of a personalized genetic risk report. Chest 161, 373–381 (2022).
Google Scholar
Hasegawa, K. et al. Clinical practice guidelines for hepatocellular carcinoma: The Japan Society of Hepatology 2021 version (5th JSH-HCC Guidelines). Hepatol. Res. 53, 383–390 (2023).
Google Scholar
Giannitrapani, L. et al. The changing epidemiology of hepatocellular carcinoma : experience of a single center. Biomed. Res. Int. 2020, 5309307 (2020).
Google Scholar
link
